-
1
-
-
0035666578
-
The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches
-
DOI 10.1016/S0006-3223(01)01303-8, PII S0006322301013038
-
Lieberman JA, Perkins D, Belger A et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 50(11), 884-897 (2001). (Pubitemid 34023591)
-
(2001)
Biological Psychiatry
, vol.50
, Issue.11
, pp. 884-897
-
-
Lieberman, J.A.1
Perkins, D.2
Belger, A.3
Chakos, M.4
Jarskog, F.5
Boteva, K.6
Gilmore, J.7
-
2
-
-
0029993441
-
Psychobiologic correlates of treatment response in schizophrenia
-
DOI 10.1016/0893-133X(95)00200-W
-
Lieberman JA, Alvir JM, Koreen A et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 14(3 Suppl.), 13S-21S (1996). (Pubitemid 26096725)
-
(1996)
Neuropsychopharmacology
, vol.14
, Issue.3 SUPPL.
-
-
Lieberman, J.A.1
Alvir, J.M.2
Koreen, A.3
Geisler, S.4
Chakos, M.5
Sheitman, B.6
Woerner, M.7
-
3
-
-
26444464824
-
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis
-
Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 162(9), 1744-1746 (2005).
-
(2005)
Am. J. Psychiatry
, vol.162
, Issue.9
, pp. 1744-1746
-
-
Perkins, D.O.1
Gu, H.2
Boteva, K.3
Lieberman, J.A.4
-
4
-
-
0023812652
-
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
-
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45(9), 789-796 (1988).
-
(1988)
Arch. Gen. Psychiatry
, vol.45
, Issue.9
, pp. 789-796
-
-
Kane, J.1
Honigfeld, G.2
Singer, J.3
Meltzer, H.4
-
5
-
-
0036159250
-
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder
-
DOI 10.1176/appi.ajp.159.2.255
-
Volavka J, Czobor P, Sheitman B et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 159(2), 255-262 (2002). (Pubitemid 34126903)
-
(2002)
American Journal of Psychiatry
, vol.159
, Issue.2
, pp. 255-262
-
-
Volavka, J.1
Czobor, P.2
Sheitman, B.3
Lindenmayer, J.-P.4
Citrome, L.5
McEvoy, J.P.6
Cooper, T.B.7
Chakos, M.8
Lieberman, J.A.9
-
6
-
-
0023606101
-
The positive and negative syndrome scale (PANSS) for schizophrenia
-
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13(2), 261-276 (1987). (Pubitemid 18039085)
-
(1987)
Schizophrenia Bulletin
, vol.13
, Issue.2
, pp. 261-276
-
-
Kay, S.R.1
Fiszbein, A.2
Opler, L.A.3
-
7
-
-
2442545310
-
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
-
Lindenmayer JP, Czobor P, Volavka J et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J. Clin. Psychiatry 65(4), 551-556 (2004).
-
(2004)
J. Clin. Psychiatry
, vol.65
, Issue.4
, pp. 551-556
-
-
Lindenmayer, J.P.1
Czobor, P.2
Volavka, J.3
-
8
-
-
1642367338
-
Managing treatment-resistant schizophrenia: Evidence from randomized clinical trials
-
Citrome L, Bilder RM, Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J. Psychiatr. Pract. 8(4), 205-215 (2002).
-
(2002)
J. Psychiatr. Pract.
, vol.8
, Issue.4
, pp. 205-215
-
-
Citrome, L.1
Bilder, R.M.2
Volavka, J.3
-
9
-
-
47149103828
-
Heterogeneity of violence in schizophrenia and implications for long-term treatment
-
DOI 10.1111/j.1742-1241.2008.01797.x
-
Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int. J. Clin. Pract. 62(8), 1237-1245 (2008). (Pubitemid 351977615)
-
(2008)
International Journal of Clinical Practice
, vol.62
, Issue.8
, pp. 1237-1245
-
-
Volavka, J.1
Citrome, L.2
-
10
-
-
79951579967
-
Measuring psychosocial outcomes in schizophrenia patients
-
Figueira ML, Brissos S. Measuring psychosocial outcomes in schizophrenia patients. Curr. Opin. Psychiatry 24(2), 91-99 (2011).
-
(2011)
Curr. Opin. Psychiatry
, vol.24
, Issue.2
, pp. 91-99
-
-
Figueira, M.L.1
Brissos, S.2
-
11
-
-
0034022621
-
Development, reliability and acceptability of a new version of the DSM- IV Social Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning
-
DOI 10.1034/j.1600-0447.2000.101004323.x
-
Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 101(4), 323-329 (2000). (Pubitemid 30173584)
-
(2000)
Acta Psychiatrica Scandinavica
, vol.101
, Issue.4
, pp. 323-329
-
-
Morosini, P.-L.1
Magliano, L.2
Brambilla, L.3
Ugolini, S.4
Pioli, R.5
-
12
-
-
58249135027
-
Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function
-
Kleinman L, Lieberman J, Dube S et al. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophr. Res. 107(2-3), 275-285 (2009).
-
(2009)
Schizophr. Res.
, vol.107
, Issue.2-3
, pp. 275-285
-
-
Kleinman, L.1
Lieberman, J.2
Dube, S.3
-
13
-
-
0035222398
-
UCSD Performance-Based Skills Assessment: Development of a New Measure of Everyday Functioning for Severely Mentally Ill Adults
-
Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr. Bull. 27(2), 235-245 (2001). (Pubitemid 33644299)
-
(2001)
Schizophrenia Bulletin
, vol.27
, Issue.2
, pp. 235-245
-
-
Patterson, T.L.1
Goldman, S.2
McKibbin, C.L.3
Hughs, T.4
Jeste, D.V.5
-
14
-
-
14844334624
-
Remission in schizophrenia: Proposed criteria and rationale for consensus
-
DOI 10.1176/appi.ajp.162.3.441
-
Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162(3), 441-449 (2005). (Pubitemid 40343909)
-
(2005)
American Journal of Psychiatry
, vol.162
, Issue.3
, pp. 441-449
-
-
Andreasen, N.C.1
Carpenter Jr., W.T.2
Kane, J.M.3
Lasser, R.A.4
Marder, S.R.5
Weinberger, D.R.6
-
15
-
-
79951577718
-
The concepts of remission and recovery in schizophrenia
-
Emsley R, Chiliza B, Asmal L, Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr. Opin. Psychiatry 24(2), 114-121 (2011).
-
(2011)
Curr. Opin. Psychiatry
, vol.24
, Issue.2
, pp. 114-121
-
-
Emsley, R.1
Chiliza, B.2
Asmal, L.3
Lehloenya, K.4
-
16
-
-
24344478615
-
Pharmacological treatments for first-episode schizophrenia
-
DOI 10.1093/schbul/sbi032
-
Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophr. Bull. 31(3), 705-722 (2005). (Pubitemid 41253320)
-
(2005)
Schizophrenia Bulletin
, vol.31
, Issue.3
, pp. 705-722
-
-
Robinson, D.G.1
Woerner, M.G.2
Delman, H.M.3
Kane, J.M.4
-
17
-
-
0036773689
-
Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature
-
Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 63(10), 892-909 (2002). (Pubitemid 35231730)
-
(2002)
Journal of Clinical Psychiatry
, vol.63
, Issue.10
, pp. 892-909
-
-
Lacro, J.P.1
Dunn, L.B.2
Dolder, C.R.3
Leckband, S.G.4
Jeste, D.V.5
-
18
-
-
0036942527
-
Predictors of noncompliance in patients with schizophrenia
-
Perkins DO. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 63(12), 1121-1128 (2002). (Pubitemid 36084056)
-
(2002)
Journal of Clinical Psychiatry
, vol.63
, Issue.12
, pp. 1121-1128
-
-
Perkins, D.O.1
-
19
-
-
35649028046
-
Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review
-
DOI 10.1093/schbul/sbm002
-
Lincoln TM, Lüllmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophr. Bull. 33(6), 1324-1342 (2007). (Pubitemid 350022767)
-
(2007)
Schizophrenia Bulletin
, vol.33
, Issue.6
, pp. 1324-1342
-
-
Lincoln, T.M.1
Lullmann, E.2
Rief, W.3
-
20
-
-
0025226205
-
Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study
-
Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264(19), 2511-2518 (1990).
-
(1990)
JAMA
, vol.264
, Issue.19
, pp. 2511-2518
-
-
Regier, D.A.1
Farmer, M.E.2
Rae, D.S.3
-
21
-
-
0036735166
-
Optimal dosing of atypical antipsychotics in adults: A review of the current evidence
-
Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv. Rev. Psychiatry 10(5), 280-291 (2002).
-
(2002)
Harv. Rev. Psychiatry
, vol.10
, Issue.5
, pp. 280-291
-
-
Citrome, L.1
Volavka, J.2
-
22
-
-
58049157203
-
Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis
-
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657), 31-41 (2009).
-
(2009)
Lancet
, vol.373
, Issue.9657
, pp. 31-41
-
-
Leucht, S.1
Corves, C.2
Arbter, D.3
Engel, R.R.4
Li, C.5
Davis, J.M.6
-
23
-
-
60349086480
-
A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
-
Leucht S, Komossa K, Rummel-Kluge C et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 166(2), 152-163 (2009).
-
(2009)
Am. J. Psychiatry
, vol.166
, Issue.2
, pp. 152-163
-
-
Leucht, S.1
Komossa, K.2
Rummel-Kluge, C.3
-
24
-
-
62849099049
-
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
-
Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 14(4), 429-447 (2009).
-
(2009)
Mol. Psychiatry
, vol.14
, Issue.4
, pp. 429-447
-
-
Leucht, S.1
Arbter, D.2
Engel, R.R.3
Kissling, W.4
Davis, J.M.5
-
25
-
-
85047698267
-
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
-
DOI 10.1176/appi.ajp.163.4.600
-
McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163(4), 600-610 (2006). (Pubitemid 44464569)
-
(2006)
American Journal of Psychiatry
, vol.163
, Issue.4
, pp. 600-610
-
-
McEvoy, J.P.1
Lieberman, J.A.2
Stroup, T.S.3
Davis, S.M.4
Meltzer, H.Y.5
Rosenheck, R.A.6
Swartz, M.S.7
Perkins, D.O.8
Keefe, R.S.E.9
Davis, C.E.10
Severe, J.11
Hsiao, J.K.12
-
26
-
-
0026772116
-
Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine
-
Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch. Gen. Psychiatry 49(5), 345-353 (1992).
-
(1992)
Arch. Gen. Psychiatry
, vol.49
, Issue.5
, pp. 345-353
-
-
Pickar, D.1
Owen, R.R.2
Litman, R.E.3
Konicki, E.4
Gutierrez, R.5
Rapaport, M.H.6
-
27
-
-
0027972344
-
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
-
Breier A, Buchanan RW, Kirkpatrick B et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry 151(1), 20-26 (1994). (Pubitemid 24020107)
-
(1994)
American Journal of Psychiatry
, vol.151
, Issue.1
, pp. 20-26
-
-
Breier, A.1
Buchanan, R.W.2
Kirkpatrick, B.3
Davis, O.R.4
Irish, D.5
Summerfelt, A.6
Carpenter Jr., W.T.7
-
28
-
-
10544235439
-
Childhood-onset schizophrenia: A double-blind clozapine-haloperidol comparison
-
Kumra S, Frazier JA, Jacobsen LK et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch. Gen. Psychiatry 53(12), 1090-1097 (1996). (Pubitemid 26422059)
-
(1996)
Archives of General Psychiatry
, vol.53
, Issue.12
, pp. 1090-1097
-
-
Kumra, S.1
Frazier, J.A.2
Jacobsen, L.K.3
McKenna, K.4
Gordon, C.T.5
Lenane, M.C.6
Hamburger, S.D.7
Smith, A.K.8
Albus, K.E.9
Alaghband-Rad, J.10
Rapoport, J.L.11
-
29
-
-
0030825390
-
A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia
-
Hong CJ, Chen JY, Chiu HJ, Sim CB. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int. Clin. Psychopharmacol. 12(3), 123-130 (1997). (Pubitemid 27283319)
-
(1997)
International Clinical Psychopharmacology
, vol.12
, Issue.3
, pp. 123-130
-
-
Hong, C.J.1
Chen, J.Y.2
Chiu, H.J.3
Sim, C.B.4
-
30
-
-
0030756517
-
A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
-
DOI 10.1056/NEJM199709183371202
-
Rosenheck R, Cramer J, Xu W et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N. Engl. J. Med. 337(12), 809-815 (1997). (Pubitemid 27391630)
-
(1997)
New England Journal of Medicine
, vol.337
, Issue.12
, pp. 809-815
-
-
Rosenheck, R.1
Cramer, J.2
Xu, W.3
Thomas, J.4
Henderson, W.5
Frisman, L.6
Fye, C.7
Charney, D.8
-
31
-
-
0031746826
-
Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome
-
Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry 155(6), 751-760 (1998). (Pubitemid 28252653)
-
(1998)
American Journal of Psychiatry
, vol.155
, Issue.6
, pp. 751-760
-
-
Buchanan, R.W.1
Breier, A.2
Kirkpatrick, B.3
Ball, P.4
Carpenter, W.T.5
-
32
-
-
0034799836
-
Clozapine and haloperidol in moderately refractory schizophrenia: A 6-month randomized and double-blind comparison
-
Kane JM, Marder SR, Schooler NR et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch. Gen. Psychiatry 58(10), 965-972 (2001). (Pubitemid 32937920)
-
(2001)
Archives of General Psychiatry
, vol.58
, Issue.10
, pp. 965-972
-
-
Kane, J.M.1
Marder, S.R.2
Schooler, N.R.3
Wirshing, W.C.4
Umbricht, D.5
Baker, R.W.6
Wirshing, D.A.7
Safferman, A.8
Ganguli, R.9
McMeniman, M.10
Borenstein, M.11
-
33
-
-
0036268294
-
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
-
DOI 10.1176/appi.ajp.159.6.1018
-
Bilder RM, Goldman RS, Volavka J et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159(6), 1018-1028 (2002). (Pubitemid 34586949)
-
(2002)
American Journal of Psychiatry
, vol.159
, Issue.6
, pp. 1018-1028
-
-
Bilder, R.M.1
Goldman, R.S.2
Volavka, J.3
Czobor, P.4
Hoptman, M.5
Sheitman, B.6
Lindenmayer, J.-P.7
Citrome, L.8
McEvoy, J.9
Kunz, M.10
Chakos, M.11
Cooper, T.B.12
Horowitz, T.L.13
Lieberman, J.A.14
-
34
-
-
0031978034
-
Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
-
Bondolfi G, Dufour H, Patris M et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am. J. Psychiatry 155(4), 499-504 (1998). (Pubitemid 28207445)
-
(1998)
American Journal of Psychiatry
, vol.155
, Issue.4
, pp. 499-504
-
-
Bondolfi, G.1
Dufour, H.2
Patris, M.3
May, J.P.4
Billeter, U.5
Eap, C.B.6
Baumann, P.7
Kasas, A.8
Juvet, P.9
Blajev, B.10
Meylan, C.11
Bertschy, G.12
Souche, A.13
Amarilli, P.14
Kastler, B.15
Rogue, P.16
Haumonte, M.-T.17
Bonin, B.18
-
35
-
-
0032884391
-
Risperidone in treatment-refractory schizophrenia
-
Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. Am. J. Psychiatry 156(9), 1374-1379 (1999). (Pubitemid 29416533)
-
(1999)
American Journal of Psychiatry
, vol.156
, Issue.9
, pp. 1374-1379
-
-
Wirshing, D.A.1
Marshall Jr., B.D.2
Green, M.F.3
Mintz, J.4
Marder, S.R.5
Wirshing, W.C.6
-
36
-
-
0033017428
-
Risperidone versus haloperidol on secondary memory: Can newer medications aid learning?
-
Kern RS, Green MF, Marshall BD Jr et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr. Bull. 25(2), 223-232 (1999). (Pubitemid 29272502)
-
(1999)
Schizophrenia Bulletin
, vol.25
, Issue.2
, pp. 223-232
-
-
Kern, R.S.1
Green, M.F.2
Marshall Jr., B.D.3
Wirshing, W.C.4
Wirshing, D.5
McGurk, S.R.6
Marder, S.R.7
Mintz, J.8
-
37
-
-
0030967398
-
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
-
Green MF, Marshall BD Jr, Wirshing WC et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry 154(6), 799-804 (1997). (Pubitemid 27230102)
-
(1997)
American Journal of Psychiatry
, vol.154
, Issue.6
, pp. 799-804
-
-
Green, M.F.1
Marshall Jr., B.D.2
Wirshing, W.C.3
Ames, D.4
Marder, S.R.5
McGurk, S.6
Kern, R.S.7
Mintz, J.8
-
38
-
-
0033047901
-
Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, Parkinsonian side effects, and neuroendocrine response
-
Breier AF, Malhotra AK, Su TP et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. J. Psychiatry 156(2), 294-298 (1999). (Pubitemid 29077121)
-
(1999)
American Journal of Psychiatry
, vol.156
, Issue.2
, pp. 294-298
-
-
Breier, A.F.1
Malhotra, A.K.2
Su, T.-P.3
Pinals, D.A.4
Elman, I.5
Adler, C.M.6
Lafargue, R.T.7
Clifton, A.8
Pickar, D.9
-
39
-
-
0033815876
-
Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study
-
Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimón R. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 24(6), 911-922 (2000).
-
(2000)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.24
, Issue.6
, pp. 911-922
-
-
Wahlbeck, K.1
Cheine, M.2
Tuisku, K.3
Ahokas, A.4
Joffe, G.5
Rimón, R.6
-
40
-
-
0034888548
-
A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia
-
DOI 10.1176/appi.ajp.158.8.1305
-
Azorin JM, Spiegel R, Remington G et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am. J. Psychiatry 158(8), 1305-1313 (2001). (Pubitemid 32717707)
-
(2001)
American Journal of Psychiatry
, vol.158
, Issue.8
, pp. 1305-1313
-
-
Azorin, J.-M.1
Spiegel, R.2
Remington, G.3
Vanelle, J.-M.4
Pere, J.-J.5
Giguere, M.6
Bourdeix, I.7
-
41
-
-
0034761326
-
Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: A randomized double-blind study
-
Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int. Clin Psychopharmacol. 16(6), 325-330 (2001).
-
(2001)
Int. Clin Psychopharmacol.
, vol.16
, Issue.6
, pp. 325-330
-
-
Zhang, X.Y.1
Zhou, D.F.2
Cao, L.Y.3
Zhang, P.Y.4
Wu, G.Y.5
Shen, Y.C.6
-
42
-
-
0036853362
-
Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia
-
DOI 10.1053/comp.2002.33499
-
Liberman RP, Gutkind D, Mintz J et al. Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia. Compr. Psychiatry 43(6), 469-473 (2002). (Pubitemid 35375524)
-
(2002)
Comprehensive Psychiatry
, vol.43
, Issue.6
, pp. 469-473
-
-
Liberman, R.P.1
Gutkind, D.2
Mintz, J.3
Green, M.4
Marshall Jr., B.D.5
Robertson, M.J.6
Hayden, J.7
-
43
-
-
23644457491
-
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia
-
DOI 10.1097/01.wnf.0000172993.89879.0f
-
Conley RR, Kelly DL, Nelson MW et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin. Neuropharmacol. 28(4), 163-168 (2005). (Pubitemid 41134242)
-
(2005)
Clinical Neuropharmacology
, vol.28
, Issue.4
, pp. 163-168
-
-
Conley, R.R.1
Kelly, D.L.2
Nelson, M.W.3
Richardson, C.M.4
Feldman, S.5
Benham, R.6
Steiner, P.7
Yu, Y.8
Khan, I.9
McMullen, R.10
Gale, E.11
Mackowick, M.12
Love, R.C.13
-
44
-
-
0031748732
-
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
-
Conley RR, Tamminga CA, Bartko JJ et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry 155(7), 914-920 (1998). (Pubitemid 28307603)
-
(1998)
American Journal of Psychiatry
, vol.155
, Issue.7
, pp. 914-920
-
-
Conley, R.R.1
Tamminga, C.A.2
Bartko, J.J.3
Richardson, C.4
Peszke, M.5
Lingle, J.6
Hegerty, J.7
Love, R.8
Gounaris, C.9
Zaremba, S.10
-
45
-
-
0033558072
-
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia
-
DOI 10.1016/S0006-3223(98)00291-1, PII S0006322398002911
-
Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psychiatry 45(4), 403-411 (1999). (Pubitemid 29130436)
-
(1999)
Biological Psychiatry
, vol.45
, Issue.4
, pp. 403-411
-
-
Breier, A.1
Hamilton, S.H.2
-
46
-
-
0035060791
-
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine
-
DOI 10.1016/S0006-3223(00)01026-X, PII S000632230001026X
-
Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry 49(1), 52-63 (2001). (Pubitemid 32332954)
-
(2001)
Biological Psychiatry
, vol.49
, Issue.1
, pp. 52-63
-
-
Tollefson, G.D.1
Birkett, M.A.2
Kiesler, G.M.3
Wood, A.J.4
-
47
-
-
0344851930
-
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: A double-blind, crossover study [5]
-
Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J. Clin. Psychopharmacol. 23(6), 668-671 (2003). (Pubitemid 37443202)
-
(2003)
Journal of Clinical Psychopharmacology
, vol.23
, Issue.6
, pp. 668-671
-
-
Conley, R.R.1
Kelly, D.L.2
Richardson, C.M.3
Tamminga, C.A.4
Carpenter Jr., W.T.5
-
48
-
-
0842327252
-
Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia
-
DOI 10.1023/B:ACLI.0000008171.90644.f8
-
Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT Jr. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann. Clin. Psychiatry 15(3-4), 181-186 (2003). (Pubitemid 38176337)
-
(2003)
Annals of Clinical Psychiatry
, vol.15
, Issue.3-4
, pp. 181-186
-
-
Kelly, D.L.1
Conley, R.R.2
Richardson, C.M.3
Tamminga, C.A.4
Carpenter Jr., W.T.5
-
49
-
-
10744231049
-
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
-
DOI 10.1016/j.pnpbp.2003.09.033
-
Bitter I, Dossenbach MR, Brook S et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 28(1), 173-180 (2004). (Pubitemid 37548509)
-
(2004)
Progress in Neuro-Psychopharmacology and Biological Psychiatry
, vol.28
, Issue.1
, pp. 173-180
-
-
Bitter, I.1
Dossenbach, M.R.K.2
Brook, S.3
Feldman, P.D.4
Metcalfe, S.5
Gagiano, C.A.6
Furedi, J.7
Bartko, G.8
Janka, Z.9
Banki, C.M.10
Kovacs, G.11
Breier, A.12
-
50
-
-
11844256301
-
Olanzapine treatment of residual positive and negative symptoms
-
DOI 10.1176/appi.ajp.162.1.124
-
Buchanan RW, Ball MP, Weiner E et al. Olanzapine treatment of residual positive and negative symptoms. Am. J. Psychiatry 162(1), 124-129 (2005). (Pubitemid 40095681)
-
(2005)
American Journal of Psychiatry
, vol.162
, Issue.1
, pp. 124-129
-
-
Buchanan, R.W.1
Ball, M.P.2
Weiner, E.3
Kirkpatrick, B.4
Gold, J.M.5
McMahon, R.P.6
Carpenter Jr., W.T.7
-
51
-
-
33745726692
-
Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison
-
Shaw P, Sporn A, Gogtay N et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch. Gen. Psychiatry 63(7), 721-730 (2006).
-
(2006)
Arch. Gen. Psychiatry
, vol.63
, Issue.7
, pp. 721-730
-
-
Shaw, P.1
Sporn, A.2
Gogtay, N.3
-
52
-
-
41549124139
-
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia
-
Meltzer HY, Bobo WV, Roy A et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 69(2), 274-285 (2008). (Pubitemid 351469271)
-
(2008)
Journal of Clinical Psychiatry
, vol.69
, Issue.2
, pp. 274-285
-
-
Meltzer, H.Y.1
Bobo, W.V.2
Roy, A.3
Jayathilake, K.4
Chen, Y.5
Ertugrul, A.6
Yagcioglu, A.E.A.7
Small, J.G.8
-
53
-
-
38949096818
-
Clozapine and "High-Dose" Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison
-
DOI 10.1016/j.biopsych.2007.04.043, PII S0006322307004799
-
Kumra S, Kranzler H, Gerbino-Rosen G et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol. Psychiatry 63(5), 524-529 (2008). (Pubitemid 351220784)
-
(2008)
Biological Psychiatry
, vol.63
, Issue.5
, pp. 524-529
-
-
Kumra, S.1
Kranzler, H.2
Gerbino-Rosen, G.3
Kester, H.M.4
DeThomas, C.5
Kafantaris, V.6
Correll, C.U.7
Kane, J.M.8
-
54
-
-
0034075361
-
A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment
-
Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int. Clin. Psychopharmacol. 15(3), 121-131 (2000). (Pubitemid 30326047)
-
(2000)
International Clinical Psychopharmacology
, vol.15
, Issue.3
, pp. 121-131
-
-
Emsley, R.A.1
Raniwalla, J.2
Bailey, P.J.3
Jones, A.M.4
-
55
-
-
31744435890
-
Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia
-
DOI 10.1097/01.yic.0000182114.65134.81
-
Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int. Clin. Psychopharmacol. 21(1), 21-28 (2006). (Pubitemid 43175119)
-
(2006)
International Clinical Psychopharmacology
, vol.21
, Issue.1
, pp. 21-28
-
-
Kane, J.M.1
Khanna, S.2
Rajadhyaksha, S.3
Giller, E.4
-
56
-
-
67649842418
-
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study
-
Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr. Res. 113(1), 112-121 (2009).
-
(2009)
Schizophr. Res.
, vol.113
, Issue.1
, pp. 112-121
-
-
Sacchetti, E.1
Galluzzo, A.2
Valsecchi, P.3
Romeo, F.4
Gorini, B.5
Warrington, L.6
-
57
-
-
33847656202
-
Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study versus perphenazine
-
Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J. Clin. Psychiatry 68(2), 213-223 (2007). (Pubitemid 46362642)
-
(2007)
Journal of Clinical Psychiatry
, vol.68
, Issue.2
, pp. 213-223
-
-
Kane, J.M.1
Meltzer, H.Y.2
Carson Jr., W.H.3
McQuade, R.D.4
Marcus, R.N.5
Sanchez, R.6
-
58
-
-
33746174667
-
Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: A double-blind randomized trial
-
Lal S, Thavundayil JX, Nair NP et al. Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. J. Psychiatry Neurosci. 31(4), 271-279 (2006). (Pubitemid 44085833)
-
(2006)
Journal of Psychiatry and Neuroscience
, vol.31
, Issue.4
, pp. 271-279
-
-
Lal, S.1
Thavundayil, J.X.2
Nair, N.P.V.3
Annable, L.4
Kin, N.M.K.N.Y.5
Gabriel, A.6
Schwartz, G.7
-
59
-
-
68149160037
-
Oral antipsychotics for the treatment of schizophrenia: Heterogeneity in efficacy and tolerability should drive decision-making
-
Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin. Pharmacother. 10(12), 1917-1928 (2009).
-
(2009)
Expert Opin. Pharmacother.
, vol.10
, Issue.12
, pp. 1917-1928
-
-
Volavka, J.1
Citrome, L.2
-
60
-
-
0037278766
-
Antipsychotic medication coprescribing in a large state hospital system
-
DOI 10.1002/pds.783
-
Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol. Drug Saf. 12(1), 41-48 (2003). (Pubitemid 36192948)
-
(2003)
Pharmacoepidemiology and Drug Safety
, vol.12
, Issue.1
, pp. 41-48
-
-
Jaffe, A.B.1
Levine, J.2
-
61
-
-
17144391387
-
Monotherapy versus polypharmacy for hospitalized psychiatric patients
-
Citrome L, Jaffe A, Levine J. Monotherapy versus polypharmacy for hospitalized psychiatric patients. Am. J. Psychiatry 162(3), 631 (2005).
-
(2005)
Am. J. Psychiatry
, vol.162
, Issue.3
, pp. 631
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
-
62
-
-
0024443180
-
Clozapine in China: A review and preview of US/PRC collaboration
-
Potter WZ, Ko GN, Zhang LD, Yan WW. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berl.) 99(Suppl.), S87-S91 (1989). (Pubitemid 19244148)
-
(1989)
Psychopharmacology
, vol.99
, Issue.SUPPL.
-
-
Potter, W.Z.1
Ko, G.N.2
Zhang, L.D.3
Yan, W.4
-
63
-
-
0030691937
-
Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study
-
Shiloh R, Zemishlany Z, Aizenberg D et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br. J. Psychiatry 171, 569-573 (1997). (Pubitemid 27527329)
-
(1997)
British Journal of Psychiatry
, vol.171
, Issue.DEC.
, pp. 569-573
-
-
Shiloh, R.1
Zemishlany, Z.2
Aizenberg, D.3
Radwan, M.4
Schwartz, B.5
Dorfman-Etrog, P.6
Modai, I.7
Khaikin, M.8
Weizman, A.9
-
64
-
-
11844304940
-
Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial
-
DOI 10.1176/appi.ajp.162.1.130
-
Josiassen RC, Joseph A, Kohegyi E et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 162(1), 130-136 (2005). (Pubitemid 40095682)
-
(2005)
American Journal of Psychiatry
, vol.162
, Issue.1
, pp. 130-136
-
-
Josiassen, R.C.1
Joseph, A.2
Kohegyi, E.3
Stokes, S.4
Dadvand, M.5
Paing, W.W.6
Shaughnessy, R.A.7
-
65
-
-
13844311144
-
A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety
-
Anil Yaciolu AE, Kivircik Akdede BB, Turgut TI et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J. Clin. Psychiatry 66(1), 63-72 (2005).
-
(2005)
J. Clin. Psychiatry
, vol.66
, Issue.1
, pp. 63-72
-
-
Anil Yaciolu, A.E.1
Kivircik Akdede, B.B.2
Turgut, T.I.3
-
66
-
-
33846025408
-
A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: Effects on cognition
-
Akdede BB, Anil Yaciolu AE, Alptekin K et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J. Clin. Psychiatry 67(12), 1912-1919 (2006). (Pubitemid 46048188)
-
(2006)
Journal of Clinical Psychiatry
, vol.67
, Issue.12
, pp. 1912-1919
-
-
Akdede, B.B.K.1
Yagcioglu, A.E.A.2
Alptekin, K.3
Turgut, T.I.4
Tumuklu, M.5
Yazici, M.K.6
Jayathilake, K.7
Tunca, Z.8
Gogus, A.9
Meltzer, H.Y.10
-
67
-
-
32044464964
-
Clozapine alone versus clozapine and risperidone with refractory schizophrenia
-
DOI 10.1056/NEJMoa053222
-
Honer WG, Thornton AE, Chen EY et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N. Engl. J. Med. 354(5), 472-482 (2006). (Pubitemid 43200298)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.5
, pp. 472-482
-
-
Honer, W.G.1
Thornton, A.E.2
Chen, E.Y.H.3
Chan, R.C.K.4
Wong, J.O.Y.5
Bergmann, A.6
Falkai, P.7
Pomarol-Clotet, E.8
McKenna, P.J.9
Stip, E.10
Williams, R.11
MacEwan, G.W.12
Wasan, K.13
Procyshyn, R.14
-
68
-
-
34147137079
-
Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial
-
DOI 10.1016/j.schres.2006.12.030, PII S0920996407000321
-
Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr. Res. 92(1-3), 90-94 (2007). (Pubitemid 46561216)
-
(2007)
Schizophrenia Research
, vol.92
, Issue.1-3
, pp. 90-94
-
-
Freudenreich, O.1
Henderson, D.C.2
Walsh, J.P.3
Culhane, M.A.4
Goff, D.C.5
-
69
-
-
78651343292
-
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine
-
Weiner E, Conley RR, Ball MP et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 35(11), 2274-2283 (2010).
-
(2010)
Neuropsychopharmacology
, vol.35
, Issue.11
, pp. 2274-2283
-
-
Weiner, E.1
Conley, R.R.2
Ball, M.P.3
-
70
-
-
33645215658
-
Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: A randomized, double-blind, placebo-controlled cross-over study
-
DOI 10.1097/01.yic.0000188216.92408.69, PII 0000485020060300000005
-
Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo controlled cross-over study. Int. Clin. Psychopharmacol. 21(2), 99-103 (2006). (Pubitemid 43740317)
-
(2006)
International Clinical Psychopharmacology
, vol.21
, Issue.2
, pp. 99-103
-
-
Kreinin, A.1
Novitski, D.2
Weizman, A.3
-
71
-
-
38849155770
-
Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial
-
DOI 10.1055/s-2007-993209
-
Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 41(1), 24-28 (2008). (Pubitemid 351195889)
-
(2008)
Pharmacopsychiatry
, vol.41
, Issue.1
, pp. 24-28
-
-
Assion, H.-J.1
Reinbold, H.2
Lemanski, S.3
Basilowski, M.4
Juckel, G.5
-
72
-
-
34247846196
-
Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study
-
Genç Y, Taner E, Candansayar S. Comparison of clozapine- amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv. Ther. 24(1), 1-13 (2007). (Pubitemid 46700860)
-
(2007)
Advances in Therapy
, vol.24
, Issue.1
, pp. 1-13
-
-
Genc, Y.1
Taner, E.2
Candansayar, S.3
-
73
-
-
45249113944
-
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial
-
Chang JS, Ahn YM, Park HJ et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 69(5), 720-731 (2008). (Pubitemid 351838681)
-
(2008)
Journal of Clinical Psychiatry
, vol.69
, Issue.5
, pp. 720-731
-
-
Chang, J.S.1
Ahn, Y.M.2
Park, H.J.3
Lee, K.Y.4
Kim, S.H.5
Kang, U.G.6
Kim, Y.S.7
-
74
-
-
77957230409
-
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trial
-
Fleischhacker WW, Heikkinen ME, Olié JP et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 13(8), 1115-1125 (2010).
-
(2010)
Int. J. Neuropsychopharmacol.
, vol.13
, Issue.8
, pp. 1115-1125
-
-
Fleischhacker, W.W.1
Heikkinen, M.E.2
Olié, J.P.3
-
75
-
-
79952360373
-
Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study
-
Muscatello MR, Bruno A, Pandolfo G et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr. Res. 127(1-3), 93-99 (2011).
-
(2011)
Schizophr. Res.
, vol.127
, Issue.1-3
, pp. 93-99
-
-
Muscatello, M.R.1
Bruno, A.2
Pandolfo, G.3
-
76
-
-
65349177685
-
Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: A randomised controlled clinical trial
-
Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J. Psychopharmacol. 23(3), 305-314 (2009).
-
(2009)
J. Psychopharmacol.
, vol.23
, Issue.3
, pp. 305-314
-
-
Zink, M.1
Kuwilsky, A.2
Krumm, B.3
Dressing, H.4
-
77
-
-
72849140996
-
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy
-
Kane JM, Correll CU, Goff DC et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J. Clin. Psychiatry 70(10), 1348-1357 (2009).
-
(2009)
J. Clin. Psychiatry
, vol.70
, Issue.10
, pp. 1348-1357
-
-
Kane, J.M.1
Correll, C.U.2
Goff, D.C.3
-
78
-
-
67649313808
-
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients
-
Henderson DC, Fan X, Copeland PM et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J. Clin. Psychopharmacol. 29(2), 165-169 (2009).
-
(2009)
J. Clin. Psychopharmacol.
, vol.29
, Issue.2
, pp. 165-169
-
-
Henderson, D.C.1
Fan, X.2
Copeland, P.M.3
-
79
-
-
70349229549
-
Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia
-
Shafti SS. Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia. Clin. Schizophr. Relat. Psychoses 3(2), 97-102 (2009).
-
(2009)
Clin. Schizophr. Relat. Psychoses
, vol.3
, Issue.2
, pp. 97-102
-
-
Shafti, S.S.1
-
80
-
-
1642534546
-
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: Evidence for improvement of mood symptomatology
-
DOI 10.1097/00004850-200401000-00004
-
Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int. Clin. Psychopharmacol. 19(1), 23-26 (2004). (Pubitemid 38114620)
-
(2004)
International Clinical Psychopharmacology
, vol.19
, Issue.1
, pp. 23-26
-
-
Kotler, M.1
Strous, R.D.2
Reznik, I.3
Shwartz, S.4
Weizman, A.5
Spivak, B.6
-
81
-
-
0033017285
-
Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia
-
Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology 39(2), 81-85 (1999). (Pubitemid 29118955)
-
(1999)
Neuropsychobiology
, vol.39
, Issue.2
, pp. 81-85
-
-
Takahashi, N.1
Terao, T.2
Oga, T.3
Okada, M.4
-
82
-
-
70049104227
-
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia
-
Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst. Rev. 8(3), CD006324 (2009).
-
(2009)
Cochrane Database Syst. Rev.
, vol.8
, Issue.3
-
-
Cipriani, A.1
Boso, M.2
Barbui, C.3
-
83
-
-
0034100648
-
Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998
-
DOI 10.1176/appi.ps.51.5.634
-
Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 51(5), 634-638 (2000). (Pubitemid 30256639)
-
(2000)
Psychiatric Services
, vol.51
, Issue.5
, pp. 634-638
-
-
Citrome, L.1
Levine, J.2
Allingham, B.3
-
84
-
-
0036787358
-
Use of mood stabilizers among patients with schizophrenia 1994-2001
-
Citrome L, Jaffe A, Levine J, Allingham B. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr. Serv. 53(10), 1212 (2002).
-
(2002)
Psychiatr. Serv.
, vol.53
, Issue.10
, pp. 1212
-
-
Citrome, L.1
Jaffe, A.2
Levine, J.3
Allingham, B.4
-
85
-
-
58149230875
-
Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: What is the evidence?
-
Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev. Neurother. 9(1), 55-71 (2009).
-
(2009)
Expert Rev. Neurother.
, vol.9
, Issue.1
, pp. 55-71
-
-
Citrome, L.1
-
86
-
-
62649086513
-
The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis
-
Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 109(1-3), 10-14 (2009).
-
(2009)
Schizophr. Res.
, vol.109
, Issue.1-3
, pp. 10-14
-
-
Tiihonen, J.1
Wahlbeck, K.2
Kiviniemi, V.3
-
87
-
-
54049091644
-
Schizophrenia, obesity, and antipsychotic medications: What can we do?
-
Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad. Med. 120(2), 18-33 (2008).
-
(2008)
Postgrad. Med.
, vol.120
, Issue.2
, pp. 18-33
-
-
Citrome, L.1
Vreeland, B.2
-
88
-
-
0036272768
-
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia
-
DOI 10.1176/appi.ajp.159.6.1029
-
Müller N, Riedel M, Scheppach C et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared with risperidone alone in schizophrenia. Am. J. Psychiatry 159(6), 1029-1034 (2002). (Pubitemid 34586950)
-
(2002)
American Journal of Psychiatry
, vol.159
, Issue.6
, pp. 1029-1034
-
-
Muller, N.1
Riedel, M.2
Scheppach, C.3
Brandstatter, B.4
Sokullu, S.5
Krampe, K.6
Ulmschneider, M.7
Engel, R.R.8
Moller, H.-J.9
Schwarz, M.J.10
House, M.11
Su, K.-P.12
Chang, H.-C.13
Shen, W.W.14
Agelink, M.W.15
-
89
-
-
20444405296
-
Celecoxib augmentation of continuously Ill patients with schizophrenia
-
DOI 10.1016/j.biopsych.2005.02.024, PII S0006322305001897
-
Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry 57(12), 1594-1596 (2005). (Pubitemid 40805391)
-
(2005)
Biological Psychiatry
, vol.57
, Issue.12
, pp. 1594-1596
-
-
Rapaport, M.H.1
Delrahim, K.K.2
Bresee, C.J.3
Maddux, R.E.4
Ahmadpour, O.5
Dolnak, D.6
-
90
-
-
33846620518
-
Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial
-
DOI 10.1016/j.schres.2006.11.016, PII S0920996406004956
-
Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res. 90(1-3), 179-185 (2007). (Pubitemid 46177578)
-
(2007)
Schizophrenia Research
, vol.90
, Issue.1-3
, pp. 179-185
-
-
Akhondzadeh, S.1
Tabatabaee, M.2
Amini, H.3
Ahmadi Abhari, S.A.4
Abbasi, S.H.5
Behnam, B.6
-
91
-
-
77955050321
-
Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
-
Müller N, Krause D, Dehning S et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 121(1-3), 118-124 (2010).
-
(2010)
Schizophr. Res.
, vol.121
, Issue.1-3
, pp. 118-124
-
-
Müller, N.1
Krause, D.2
Dehning, S.3
-
92
-
-
77952641170
-
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial
-
Laan W, Grobbee DE, Selten JP et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 71(5), 520-527 (2010).
-
(2010)
J. Clin. Psychiatry
, vol.71
, Issue.5
, pp. 520-527
-
-
Laan, W.1
Grobbee, D.E.2
Selten, J.P.3
-
93
-
-
0023250446
-
Adjunctive imipramine in the treatment of postpsychotic depression: A controlled trial
-
Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB. Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial. Arch. Gen. Psychiatry 44(6), 533-539 (1987). (Pubitemid 17082094)
-
(1987)
Archives of General Psychiatry
, vol.44
, Issue.6
, pp. 533-539
-
-
Siris, S.G.1
Morgan, V.2
Fagerstrom, R.3
-
94
-
-
0024459594
-
Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial
-
Kramer MS, Vogel WH, DiJohnson C et al. Antidepressants in "depressed" schizophrenic inpatients. A controlled trial. Arch. Gen. Psychiatry 46(10), 922-928 (1989). (Pubitemid 19259540)
-
(1989)
Archives of General Psychiatry
, vol.46
, Issue.10
, pp. 922-928
-
-
Kramer, M.S.1
Vogel, W.H.2
DiJohnson, C.3
Dewey, D.A.4
Sheves, P.5
Cavicchia, S.6
Litle, P.7
Schmidt, R.8
Kimes, I.9
-
95
-
-
0025113427
-
Adjunctive imipramine maintenance in post-psychotic depression/negative symptoms
-
Siris SG, Mason SE, Bermanzohn PC, Alvir JM, McCorry TA. Adjunctive imipramine maintenance in post-psychotic depression/negative symptoms. Psychopharmacol. Bull. 26(1), 91-94 (1990). (Pubitemid 20322252)
-
(1990)
Psychopharmacology Bulletin
, vol.26
, Issue.1
, pp. 91-94
-
-
Siris, S.G.1
Mason, S.E.2
Bermanzohn, P.C.3
Alvir, J.M.J.4
McCorry, T.A.5
-
96
-
-
0025936111
-
The use of antidepressants for negative symptoms in a subset of schizophrenic patients
-
Siris SG, Bermanzohn PC, Gonzalez A, Mason SE, White CV, Shuwall MA. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol. Bull. 27(3), 331-335 (1991).
-
(1991)
Psychopharmacol. Bull.
, vol.27
, Issue.3
, pp. 331-335
-
-
Siris, S.G.1
Bermanzohn, P.C.2
Gonzalez, A.3
Mason, S.E.4
White, C.V.5
Shuwall, M.A.6
-
97
-
-
0026778346
-
Adjunctive imipramine for dysphoric schizophrenic patients with past histories of cannabis abuse
-
Siris SG, Bermanzohn PC, Mason SE, Rifkin A, Alvir JM. Adjunctive imipramine for dysphoric schizophrenic patients with past histories of cannabis abuse. Prog. Neuropsychopharmacol. Biol. Psychiatry 16(4), 539-547 (1992).
-
(1992)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.16
, Issue.4
, pp. 539-547
-
-
Siris, S.G.1
Bermanzohn, P.C.2
Mason, S.E.3
Rifkin, A.4
Alvir, J.M.5
-
98
-
-
0027954581
-
Maintenance imipramine therapy for secondary depression in schizophrenia: A controlled trial
-
Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch. Gen. Psychiatry 51(2), 109-115 (1994). (Pubitemid 24054312)
-
(1994)
Archives of General Psychiatry
, vol.51
, Issue.2
, pp. 109-115
-
-
Siris, S.G.1
Bermanzohn, P.C.2
Mason, S.E.3
Shuwall, M.A.4
-
99
-
-
0028937511
-
Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia
-
Vartiainen H, Tiihonen J, Putkonen A et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr. Scand. 91(5), 348-351 (1995).
-
(1995)
Acta Psychiatr. Scand.
, vol.91
, Issue.5
, pp. 348-351
-
-
Vartiainen, H.1
Tiihonen, J.2
Putkonen, A.3
-
100
-
-
0029809081
-
Citalopram as an adjuvant in chronic schizophrenia: A double-blind placebo-controlled study
-
Salokangas RK, Saarijärvi S, Taiminen T et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr. Scand. 94(3), 175-180 (1996). (Pubitemid 26313289)
-
(1996)
Acta Psychiatrica Scandinavica
, vol.94
, Issue.3
, pp. 175-180
-
-
Salokangas, R.K.R.1
Saarijarvi, S.2
Taiminen, T.3
Kallioniemi, H.4
Lehto, H.5
Niemi, H.6
Tuominen, J.7
Ahola, V.8
Syvalahti, E.9
-
101
-
-
0030899569
-
Citalopram as an adjuvant in schizophrenia: Further evidence for a serotonergic dimension in schizophrenia
-
Taiminen TJ, Syvälahti E, Saarijärvi S et al. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int. Clin. Psychopharmacol. 12(1), 31-35 (1997). (Pubitemid 27171193)
-
(1997)
International Clinical Psychopharmacology
, vol.12
, Issue.1
, pp. 31-35
-
-
Taiminen, T.J.1
Syvalahti, E.2
Saarijarvi, S.3
Niemi, H.4
Lehto, H.5
Ahola, V.6
Salokangas, R.K.R.7
-
102
-
-
0035678743
-
Citalopram augmentation of antipsychotic treatment in older schizophrenia patients
-
DOI 10.1002/gps.508
-
Kasckow JW, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste DV. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. Int. J. Geriatr. Psychiatry 16(12), 1163-1167 (2001). (Pubitemid 34044184)
-
(2001)
International Journal of Geriatric Psychiatry
, vol.16
, Issue.12
, pp. 1163-1167
-
-
Kasckow, J.W.1
Mohamed, S.2
Thallasinos, A.3
Carroll, B.4
Zisook, S.5
Jeste, D.V.6
-
103
-
-
18844394326
-
The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia
-
DOI 10.1097/01.jcp.0000161499.58266.51
-
Friedman JI, Ocampo R, Elbaz Z et al. The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. J. Clin. Psychopharmacol. 25(3), 237-242 (2005). (Pubitemid 40685787)
-
(2005)
Journal of Clinical Psychopharmacology
, vol.25
, Issue.3
, pp. 237-242
-
-
Friedman, J.I.1
Ocampo, R.2
Elbaz, Z.3
Parrella, M.4
White, L.5
Bowler, S.6
Davis, K.L.7
Harvey, P.D.8
-
104
-
-
66349133105
-
Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: A randomized controlled trial
-
Zisook S, Kasckow JW, Golshan S et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J. Clin. Psychiatry 70(4), 562-571 (2009).
-
(2009)
J. Clin. Psychiatry
, vol.70
, Issue.4
, pp. 562-571
-
-
Zisook, S.1
Kasckow, J.W.2
Golshan, S.3
-
105
-
-
77955294108
-
Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: A randomized controlled trial
-
Zisook S, Kasckow JW, Lanouette NM et al. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. J. Clin. Psychiatry 71(7), 915-922 (2010).
-
(2010)
J. Clin. Psychiatry
, vol.71
, Issue.7
, pp. 915-922
-
-
Zisook, S.1
Kasckow, J.W.2
Lanouette, N.M.3
-
106
-
-
75749098133
-
Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: Effect on functioning
-
Kasckow J, Lanouette N, Patterson T et al. Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning. Int. J. Geriatr. Psychiatry 25(2), 183-190 (2010).
-
(2010)
Int. J. Geriatr. Psychiatry
, vol.25
, Issue.2
, pp. 183-190
-
-
Kasckow, J.1
Lanouette, N.2
Patterson, T.3
-
107
-
-
77955429638
-
Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double-blind placebo-controlled trial
-
Iancu I, Tschernihovsky E, Bodner E, Piconne AS, Lowengrub K. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. Psychiatry Res. 179(1), 19-23 (2010).
-
(2010)
Psychiatry Res.
, vol.179
, Issue.1
, pp. 19-23
-
-
Iancu, I.1
Tschernihovsky, E.2
Bodner, E.3
Piconne, A.S.4
Lowengrub, K.5
-
108
-
-
0028090031
-
Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients
-
Spina E, De Domenico P, Ruello C et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int. Clin. Psychopharmacol. 9(4), 281-285 (1994). (Pubitemid 24374889)
-
(1994)
International Clinical Psychopharmacology
, vol.9
, Issue.4
, pp. 281-285
-
-
Spina, E.1
De Domenico, P.2
Ruello, C.3
Longobardo, N.4
Gitto, C.5
Ancione, M.6
Di Rosa, A.E.7
Caputi, A.P.8
-
109
-
-
0029903904
-
Fluoxetine augmentation of clozapine treatment in patients with schizophrenia
-
Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am. J. Psychiatry 153(12), 1625-1627 (1996). (Pubitemid 26406176)
-
(1996)
American Journal of Psychiatry
, vol.153
, Issue.12
, pp. 1625-1627
-
-
Buchanan, R.W.1
Kirkpatrick, B.2
Bryant, N.3
Ball, P.4
Breier, A.5
-
110
-
-
0026686088
-
Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study
-
Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol. Psychiatry 31(7), 698-704 (1992).
-
(1992)
Biol. Psychiatry
, vol.31
, Issue.7
, pp. 698-704
-
-
Silver, H.1
Nassar, A.2
-
111
-
-
0033845691
-
Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: A placebo-controlled study
-
Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int. Clin. Psychopharmacol. 15(5), 257-261 (2000). (Pubitemid 30660960)
-
(2000)
International Clinical Psychopharmacology
, vol.15
, Issue.5
, pp. 257-261
-
-
Silver, H.1
Barash, I.2
Aharon, N.3
Kaplan, A.4
Poyurovsky, M.5
-
112
-
-
4243182676
-
Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia
-
DOI 10.1111/j.1440-1819.2004.01269.x
-
Chaichan W. Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia. Psychiatry Clin. Neurosci. 58(4), 364-368 (2004). (Pubitemid 39108537)
-
(2004)
Psychiatry and Clinical Neurosciences
, vol.58
, Issue.4
, pp. 364-368
-
-
Chaichan, W.1
-
113
-
-
0035116237
-
Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
-
Berk M, Ichim C, Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int. Clin. Psychopharmacol. 16(2), 87-92 (2001). (Pubitemid 32171833)
-
(2001)
International Clinical Psychopharmacology
, vol.16
, Issue.2
, pp. 87-92
-
-
Berk, M.1
Ichim, C.2
Brook, S.3
-
114
-
-
1542286227
-
The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: A double-blind, placebo-controlled study
-
DOI 10.1097/00004850-200403000-00003
-
Zoccali R, Muscatello MR, Cedro C et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a doubleblind, placebo-controlled study. Int. Clin. Psychopharmacol. 19(2), 71-76 (2004). (Pubitemid 38324586)
-
(2004)
International Clinical Psychopharmacology
, vol.19
, Issue.2
, pp. 71-76
-
-
Zoccali, R.1
Muscatello, M.R.2
Cedro, C.3
Neri, P.4
La Torre, D.5
Spina, E.6
Di Rosa, A.E.7
Meduri, M.8
-
115
-
-
67649723855
-
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: A double-blind, randomised, placebo-controlled clinical trial
-
Berk M, Gama CS, Sundram S et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum. Psychopharmacol. 24(3), 233-238 (2009).
-
(2009)
Hum. Psychopharmacol.
, vol.24
, Issue.3
, pp. 233-238
-
-
Berk, M.1
Gama, C.S.2
Sundram, S.3
-
116
-
-
60249102800
-
Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial
-
Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr. Res. 108(1-3), 245-251 (2009).
-
(2009)
Schizophr. Res.
, vol.108
, Issue.1-3
, pp. 245-251
-
-
Joffe, G.1
Terevnikov, V.2
Joffe, M.3
Stenberg, J.H.4
Burkin, M.5
Tiihonen, J.6
-
117
-
-
77953540588
-
Effects of add-on mirtazapine on neurocognition in schizophrenia: A double-blind, randomized, placebo-controlled study
-
Stenberg JH, Terevnikov V, Joffe M et al. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int. J. Neuropsychopharmacol. 13(4), 433-441 (2010).
-
(2010)
Int. J. Neuropsychopharmacol.
, vol.13
, Issue.4
, pp. 433-441
-
-
Stenberg, J.H.1
Terevnikov, V.2
Joffe, M.3
-
118
-
-
74449083580
-
The effect of mirtazapine add-on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial
-
Abbasi SH, Behpournia H, Ghoreshi A et al. The effect of mirtazapine add-on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr. Res. 116(2-3), 101-106 (2010).
-
(2010)
Schizophr. Res.
, vol.116
, Issue.2-3
, pp. 101-106
-
-
Abbasi, S.H.1
Behpournia, H.2
Ghoreshi, A.3
-
119
-
-
78650943515
-
Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial
-
Cho SJ, Yook K, Kim B et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(1), 208-211 (2011).
-
(2011)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.35
, Issue.1
, pp. 208-211
-
-
Cho, S.J.1
Yook, K.2
Kim, B.3
-
120
-
-
0036186944
-
Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia
-
Shiloh R, Zemishlany Z, Aizenberg D et al. Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. Int. Clin. Psychopharmacol. 17(2), 59-64 (2002). (Pubitemid 34169647)
-
(2002)
International Clinical Psychopharmacology
, vol.17
, Issue.2
, pp. 59-64
-
-
Shiloh, R.1
Zemishlany, Z.2
Aizenberg, D.3
Valevski, A.4
Bodinger, L.5
Munitz, H.6
Weizman, A.7
-
121
-
-
0344406216
-
Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: An add-on, double-blind placebo-controlled study
-
DOI 10.1016/S0924-977X(02)00155-4
-
Poyurovsky M, Koren D, Gonopolsky I et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur. Neuropsychopharmacol. 13(2), 123-128 (2003). (Pubitemid 36313287)
-
(2003)
European Neuropsychopharmacology
, vol.13
, Issue.2
, pp. 123-128
-
-
Poyurovsky, M.1
Koren, D.2
Gonopolsky, I.3
Schneidman, M.4
Fuchs, C.5
Weizman, A.6
Weizman, R.7
-
122
-
-
12144261224
-
Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: A double-blind placebo-controlled study
-
DOI 10.1097/00004850-200501000-00006
-
Jockers-Scherübl MC, Bauer A, Godemann F, Reischies FM, Selig F, Schlattmann P. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol. 20(1), 27-31 (2005). (Pubitemid 40105546)
-
(2005)
International Clinical Psychopharmacology
, vol.20
, Issue.1
, pp. 27-31
-
-
Jockers-Scherubl, M.C.1
Bauer, A.2
Godemann, F.3
Reischies, F.M.4
Selig, F.5
Schlattmann, P.6
-
123
-
-
0034830758
-
Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: A preliminary double-blind randomized placebo-controlled study
-
Schutz G, Berk M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int. Clin. Psychopharmacol. 16(5), 275-278 (2001). (Pubitemid 32822446)
-
(2001)
International Clinical Psychopharmacology
, vol.16
, Issue.5
, pp. 275-278
-
-
Schutz, G.1
Berk, M.2
-
124
-
-
56449125612
-
Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
-
Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(8), 1879-1883 (2008).
-
(2008)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.32
, Issue.8
, pp. 1879-1883
-
-
Akhondzadeh, S.1
Malek-Hosseini, M.2
Ghoreishi, A.3
Raznahan, M.4
Rezazadeh, S.A.5
-
125
-
-
13444271621
-
Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia
-
DOI 10.1176/appi.ajp.162.2.388
-
Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry 162(2), 388-390 (2005). (Pubitemid 40216224)
-
(2005)
American Journal of Psychiatry
, vol.162
, Issue.2
, pp. 388-390
-
-
Bodkin, J.A.1
Siris, S.G.2
Bermanzohn, P.C.3
Hennen, J.4
Cole, J.O.5
-
126
-
-
40549123370
-
Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
-
DOI 10.1002/hup.902
-
Amiri A, Noorbala AA, Nejatisafa AA et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Hum. Psychopharmacol. 23(2), 79-86 (2008). (Pubitemid 351359579)
-
(2008)
Human Psychopharmacology
, vol.23
, Issue.2
, pp. 79-86
-
-
Amiri, A.1
Noorbala, A.-A.2
Nejatisafa, A.-A.3
Ghoreishi, A.4
Derakhshan, M.-K.5
Khodaie-Ardakani, M.-R.6
Hajiazim, M.7
Raznahan, M.8
Akhondzadeh, S.9
-
127
-
-
0008762402
-
A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia
-
DOI 10.1097/00004714-199810000-00008
-
Lee MS, Kim YK, Lee SK, Suh KY. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J. Clin. Psychopharmacol. 18(5), 399-403 (1998). (Pubitemid 28462630)
-
(1998)
Journal of Clinical Psychopharmacology
, vol.18
, Issue.5
, pp. 399-403
-
-
Lee, M.S.1
Kim, Y.K.2
Lee, S.K.3
Suh, K.Y.4
-
128
-
-
0028030115
-
Adjunctive trazodone in the treatment of negative symptoms of schizophrenia
-
Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C, Scapicchio P. Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. Hosp. Community Psychiatry 45(12), 1220-1223 (1994). (Pubitemid 24375295)
-
(1994)
Hospital and Community Psychiatry
, vol.45
, Issue.12
, pp. 1220-1223
-
-
Decina, P.1
Mukherjee, S.2
Bocola, V.3
Saraceni, F.4
Hadjichristos, C.5
Scapicchio, P.L.6
-
129
-
-
0036635952
-
Double-blind antiglucocorticoid treatment in schizophrenia and schizoaffective disorder: A pilot study
-
Marco EJ, Wolkowitz OM, Vinogradov S, Poole JH, Lichtmacher J, Reus VI. Double-blind antiglucocorticoid treatment in schizophrenia and schizoaffective disorder: a pilot study. World J. Biol. Psychiatry 3(3), 156-161 (2002).
-
(2002)
World J. Biol. Psychiatry
, vol.3
, Issue.3
, pp. 156-161
-
-
Marco, E.J.1
Wolkowitz, O.M.2
Vinogradov, S.3
Poole, J.H.4
Lichtmacher, J.5
Reus, V.I.6
-
130
-
-
11844302940
-
Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia
-
DOI 10.1016/j.biopsych.2004.10.017, PII S0006322304010972
-
Gallagher P, Watson S, Smith MS, Ferrier IN, Young AH. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol. Psychiatry 57(2), 155-161 (2005). (Pubitemid 40094715)
-
(2005)
Biological Psychiatry
, vol.57
, Issue.2
, pp. 155-161
-
-
Gallagher, P.1
Watson, S.2
Smith, M.S.3
Ferrier, I.N.4
Young, A.H.5
-
132
-
-
0034887916
-
Guanfacine treatment of cognitive impairment in schizophrenia
-
DOI 10.1016/S0893-133X(01)00249-4, PII S0893133X01002494
-
Friedman JI, Adler DN, Temporini HD et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 25(3), 402-409 (2001). (Pubitemid 32777790)
-
(2001)
Neuropsychopharmacology
, vol.25
, Issue.3
, pp. 402-409
-
-
Friedman, J.I.1
Adler, D.N.2
Temporini, H.D.3
Kemether, E.4
Harvey, P.D.5
White, L.6
Parrella, M.7
Davis, K.L.8
-
133
-
-
38349142770
-
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia
-
Friedman JI, Carpenter D, Lu J et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J. Clin. Psychopharmacol. 28(1), 59-63 (2008).
-
(2008)
J. Clin. Psychopharmacol.
, vol.28
, Issue.1
, pp. 59-63
-
-
Friedman, J.I.1
Carpenter, D.2
Lu, J.3
-
134
-
-
66349085040
-
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia
-
Kelly DL, Buchanan RW, Boggs DL et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J. Clin. Psychiatry 70(4), 518-525 (2009).
-
(2009)
J. Clin. Psychiatry
, vol.70
, Issue.4
, pp. 518-525
-
-
Kelly, D.L.1
Buchanan, R.W.2
Boggs, D.L.3
-
135
-
-
0029811286
-
Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients
-
Allan ER, Alpert M, Sison CE, Citrome L, Laury G, Berman I. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J. Clin. Psychiatry 57(10), 455-459 (1996). (Pubitemid 26362309)
-
(1996)
Journal of Clinical Psychiatry
, vol.57
, Issue.10
, pp. 455-459
-
-
Allan, E.R.1
Alpert, M.2
Sison, C.E.3
Citrome, L.4
Laury, G.5
Berman, I.6
-
136
-
-
0035116315
-
Pindolol augmentation in aggressive schizophrenic patients: A double-blind crossover randomized study
-
Caspi N, Modai I, Barak P et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int. Clin. Psychopharmacol. 16(2), 111-115 (2001). (Pubitemid 32171836)
-
(2001)
International Clinical Psychopharmacology
, vol.16
, Issue.2
, pp. 111-115
-
-
Caspi, N.1
Modai, I.2
Barak, P.3
Waisbourd, A.4
Zbarsky, H.5
Hirschmann, S.6
Ritsner, M.7
-
137
-
-
0036501411
-
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia
-
DOI 10.1016/S0006-3223(01)01342-7, PII S0006322301013427
-
Friedman JI, Adler DN, Howanitz E et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol. Psychiatry 51(5), 349-357 (2002). (Pubitemid 34251171)
-
(2002)
Biological Psychiatry
, vol.51
, Issue.5
, pp. 349-357
-
-
Friedman, J.I.1
Adler, D.N.2
Howanitz, E.3
Harvey, P.D.4
Brenner, G.5
Temporini, H.6
White, L.7
Parrella, M.8
-
138
-
-
19244366120
-
Donepezil augmentation of clozapine monotherapy in schizophrenia patients: A double blind cross-over study
-
DOI 10.1002/hup.595
-
Stryjer R, Strous R, Bar F et al. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Hum. Psychopharmacol. 19(5), 343-346 (2004). (Pubitemid 39106875)
-
(2004)
Human Psychopharmacology
, vol.19
, Issue.5
, pp. 343-346
-
-
Stryjer, R.1
Strous, R.2
Bar, F.3
Shaked, G.4
Shiloh, R.5
Rozencwaig, S.6
Grupper, D.7
Buchman, N.8
Kotler, M.9
Rabey, J.M.10
Weizman, A.11
-
139
-
-
17544402307
-
A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia
-
DOI 10.1017/S1461145703004024
-
Tual O, Yazici KM, Anil Yaciolu AE, Göü A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 7(2), 117-123 (2004). (Pubitemid 38823278)
-
(2004)
International Journal of Neuropsychopharmacology
, vol.7
, Issue.2
, pp. 117-123
-
-
Tugal, O.1
Yazici, K.M.2
Yagcioglu, A.E.A.3
Gogus, A.4
-
140
-
-
23644433690
-
Efficacy and tolerability of low-dose donepezil in schizophrenia
-
DOI 10.1097/01.wnf.0000173714.61744.e6
-
Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin. Neuropharmacol. 28(4), 179-184 (2005). (Pubitemid 41134245)
-
(2005)
Clinical Neuropharmacology
, vol.28
, Issue.4
, pp. 179-184
-
-
Erickson, S.K.1
Schwarzkopf, S.B.2
Palumbo, D.3
Badgley-Fleeman, J.4
Smirnow, A.M.5
Light, G.A.6
-
141
-
-
27144510114
-
Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial
-
DOI 10.1007/s00213-005-2235-1
-
Freudenreich O, Herz L, Deckersbach T et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl.) 181(2), 358-363 (2005). (Pubitemid 41492206)
-
(2005)
Psychopharmacology
, vol.181
, Issue.2
, pp. 358-363
-
-
Freudenreich, O.1
Herz, L.2
Deckersbach, T.3
Evins, A.E.4
Henderson, D.C.5
Cather, C.6
Goff, D.C.7
-
142
-
-
33746423014
-
Donepezil for negative signs in elderly patients with schizophrenia: An add-on, double-blind, crossover, placebo-controlled study
-
DOI 10.1017/S1041610205003017, PII S1041610205003017
-
Mazeh D, Zemishlani H, Barak Y, Mirecki I, Paleacu D. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. Int. Psychogeriatr. 18(3), 429-436 (2006). (Pubitemid 44128317)
-
(2006)
International Psychogeriatrics
, vol.18
, Issue.3
, pp. 429-436
-
-
Mazeh, D.1
Zemishlani, H.2
Barak, Y.3
Mirecki, I.4
Paleacu, D.5
-
143
-
-
33846815311
-
Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: A double-blind, placebo-controlled study
-
DOI 10.1097/01.WNF.0000240940.67241.F6, PII 0000282620070100000002
-
Fagerlund B, Søholm B, Fink-Jensen A, Lublin H, Glenthøj BY. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin. Neuropharmacol. 30(1), 3-12 (2007). (Pubitemid 46204312)
-
(2007)
Clinical Neuropharmacology
, vol.30
, Issue.1
, pp. 3-12
-
-
Fagerlund, B.1
Soholm, B.2
Fink-Jensen, A.3
Lublin, H.4
Glenthoj, B.Y.5
-
144
-
-
34447546649
-
A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia
-
Lee BJ, Lee JG, Kim YH. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J. Psychopharmacol. 21(4), 421-427 (2007).
-
(2007)
J. Psychopharmacol.
, vol.21
, Issue.4
, pp. 421-427
-
-
Lee, B.J.1
Lee, J.G.2
Kim, Y.H.3
-
145
-
-
34249317238
-
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study
-
DOI 10.1016/j.schres.2007.01.001, PII S0920996407000503
-
Risch SC, Horner MD, McGurk SR et al. Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. Schizophr. Res. 93(1-3), 131-135 (2007). (Pubitemid 46817923)
-
(2007)
Schizophrenia Research
, vol.93
, Issue.1-3
, pp. 131-135
-
-
Risch, S.C.1
Horner, M.D.2
McGurk, S.R.3
Palecko, S.4
Markowitz, J.S.5
Nahas, Z.6
DeVane, C.L.7
-
146
-
-
56549087519
-
A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia
-
Akhondzadeh S, Gerami M, Noroozian M et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(8), 1810-1815 (2008).
-
(2008)
Prog. Neuropsychopharmacol. Biol. Psychiatry
, vol.32
, Issue.8
, pp. 1810-1815
-
-
Akhondzadeh, S.1
Gerami, M.2
Noroozian, M.3
-
147
-
-
42049123448
-
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial
-
DOI 10.1038/sj.npp.1301499, PII 1301499
-
Keefe RSE, Malhotra AK, Meltzer HY et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33(6), 1217-1228 (2008). (Pubitemid 351521707)
-
(2008)
Neuropsychopharmacology
, vol.33
, Issue.6
, pp. 1217-1228
-
-
Keefe, R.S.E.1
Malhotra, A.K.2
Meltzer, H.Y.3
Kane, J.M.4
Buchanan, R.W.5
Murthy, A.6
Sovel, M.7
Li, C.8
Goldman, R.9
-
148
-
-
33748751285
-
Galantamine improves cognition in schizophrenic patients stabilized on risperidone
-
DOI 10.1016/j.biopsych.2006.04.006, PII S0006322306004689
-
Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol. Psychiatry 60(6), 530-533 (2006). (Pubitemid 44402376)
-
(2006)
Biological Psychiatry
, vol.60
, Issue.6
, pp. 530-533
-
-
Schubert, M.H.1
Young, K.A.2
Hicks, P.B.3
-
149
-
-
33846986313
-
A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia
-
Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int. Clin. Psychopharmacol. 22(2), 63-68 (2007).
-
(2007)
Int. Clin. Psychopharmacol.
, vol.22
, Issue.2
, pp. 63-68
-
-
Lee, S.W.1
Lee, J.G.2
Lee, B.J.3
Kim, Y.H.4
-
150
-
-
46249116680
-
High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia
-
Dyer MA, Freudenreich O, Culhane MA et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr. Res. 102(1-3), 88-95 (2008).
-
(2008)
Schizophr. Res.
, vol.102
, Issue.1-3
, pp. 88-95
-
-
Dyer, M.A.1
Freudenreich, O.2
Culhane, M.A.3
-
151
-
-
67749116340
-
The effects of galantamine on psychopathology in chronic stable schizophrenia
-
Conley RR, Boggs DL, Kelly DL et al. The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin. Neuropharmacol. 32(2), 69-74 (2009).
-
(2009)
Clin. Neuropharmacol.
, vol.32
, Issue.2
, pp. 69-74
-
-
Conley, R.R.1
Boggs, D.L.2
Kelly, D.L.3
-
152
-
-
78951485005
-
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia
-
Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr. Res. 125(2-3), 267-277 (2011).
-
(2011)
Schizophr. Res.
, vol.125
, Issue.2-3
, pp. 267-277
-
-
Lindenmayer, J.P.1
Khan, A.2
-
153
-
-
72849132183
-
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine
-
de Lucena D, Fernandes BS, Berk M et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J. Clin. Psychiatry 70(10), 1416-1423 (2009).
-
(2009)
J. Clin. Psychiatry
, vol.70
, Issue.10
, pp. 1416-1423
-
-
De Lucena, D.1
Fernandes, B.S.2
Berk, M.3
-
154
-
-
62349116484
-
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
-
Lieberman JA, Papadakis K, Csernansky J et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34(5), 1322-1329 (2009).
-
(2009)
Neuropsychopharmacology
, vol.34
, Issue.5
, pp. 1322-1329
-
-
Lieberman, J.A.1
Papadakis, K.2
Csernansky, J.3
-
155
-
-
33745378627
-
Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation
-
DOI 10.1016/j.schres.2006.03.037, PII S092099640600096X
-
Sharma T, Reed C, Aasen I, Kumari V. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr. Res. 85(1-3), 73-83 (2006). (Pubitemid 43947524)
-
(2006)
Schizophrenia Research
, vol.85
, Issue.1-3
, pp. 73-83
-
-
Sharma, T.1
Reed, C.2
Aasen, I.3
Kumari, V.4
-
156
-
-
33947406279
-
Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits
-
DOI 10.1185/030079906X167372
-
Chouinard S, Stip E, Poulin J et al. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr. Med. Res. Opin. 23(3), 575-583 (2007). (Pubitemid 46456905)
-
(2007)
Current Medical Research and Opinion
, vol.23
, Issue.3
, pp. 575-583
-
-
Chouinard, S.1
Stip, E.2
Poulin, J.3
Melun, J.-P.4
Godbout, R.5
Guillem, F.6
Cohen, H.7
-
157
-
-
57349167353
-
Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia
-
Lewis DA, Cho RY, Carter CS et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 165(12), 1585-1593 (2008).
-
(2008)
Am. J. Psychiatry
, vol.165
, Issue.12
, pp. 1585-1593
-
-
Lewis, D.A.1
Cho, R.Y.2
Carter, C.S.3
-
158
-
-
79951656529
-
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
-
Buchanan RW, Keefe RS, Lieberman JA et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol. Psychiatry 69(5), 442-449 (2011).
-
(2011)
Biol. Psychiatry
, vol.69
, Issue.5
, pp. 442-449
-
-
Buchanan, R.W.1
Keefe, R.S.2
Lieberman, J.A.3
-
159
-
-
0029658545
-
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
-
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br. J. Psychiatry 169(5), 610-617 (1996).
-
(1996)
Br. J. Psychiatry
, vol.169
, Issue.5
, pp. 610-617
-
-
Heresco-Levy, U.1
Javitt, D.C.2
Ermilov, M.3
Mordel, C.4
Horowitz, A.5
Kelly, D.6
-
160
-
-
0032925438
-
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
-
DOI 10.1001/archpsyc.56.1.29
-
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56(1), 29-36 (1999). (Pubitemid 29055047)
-
(1999)
Archives of General Psychiatry
, vol.56
, Issue.1
, pp. 29-36
-
-
Heresco-Levy, U.1
Javitt, D.C.2
Ermilov, M.3
Mordel, C.4
Silipo, G.5
Lichtenstein, M.6
-
161
-
-
0032955821
-
Effect of clozapine and adjunctive high-dose glycine in treatment- resistant schizophrenia
-
Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am. J. Psychiatry 156(1), 145-147 (1999). (Pubitemid 29034896)
-
(1999)
American Journal of Psychiatry
, vol.156
, Issue.1
, pp. 145-147
-
-
Potkin, S.G.1
Jin, Y.2
Bunney, B.G.3
Costa, J.4
Gulasekaram, B.5
-
162
-
-
0034058017
-
Placebo-controlled trial of glycine added to clozapine in schizophrenia
-
DOI 10.1176/appi.ajp.157.5.826
-
Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am. J. Psychiatry 157(5), 826-828 (2000). (Pubitemid 30249667)
-
(2000)
American Journal of Psychiatry
, vol.157
, Issue.5
, pp. 826-828
-
-
Evins, A.E.1
Fitzgerald, S.M.2
Wine, L.3
Rosselli, R.4
Goff, D.C.5
-
163
-
-
0035218449
-
Adjunctive high-dose glycine in the treatment of schizophrenia
-
Javitt DC, Silipo G, Cienfuegos A et al. Adjunctive high-dose glycine in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 4(4), 385-391 (2001). (Pubitemid 33151682)
-
(2001)
International Journal of Neuropsychopharmacology
, vol.4
, Issue.4
, pp. 385-391
-
-
Javitt, D.C.1
Silipo, G.2
Cienfuegos, A.3
Shelley, A.-M.4
Bark, N.5
Park, M.6
Lindenmayer, J.-P.7
Suckow, R.8
Zukin, S.R.9
-
164
-
-
1442333154
-
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
-
DOI 10.1016/S0006-3223(03)00707-8, PII S0006322303007078
-
Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry 55(2), 165-171 (2004). (Pubitemid 38367720)
-
(2004)
Biological Psychiatry
, vol.55
, Issue.2
, pp. 165-171
-
-
Heresco-Levy, U.1
Ermilov, M.2
Lichtenberg, P.3
Bar, G.4
Javitt, D.C.5
-
165
-
-
35748969317
-
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
-
DOI 10.1176/appi.ajp.2007.06081358
-
Buchanan RW, Javitt DC, Marder SE et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164(10), 1593-1602 (2007). (Pubitemid 350069740)
-
(2007)
American Journal of Psychiatry
, vol.164
, Issue.10
, pp. 1593-1602
-
-
Buchanan, R.W.1
Javitt, D.C.2
Marder, S.R.3
Schooler, N.R.4
Gold, J.M.5
McMahon, R.P.6
Heresco-Levy, U.7
Carpenter, W.T.8
-
166
-
-
15444377601
-
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
-
DOI 10.1016/j.biopsych.2004.12.037
-
Heresco-Levy U, Javitt DC, Ebstein R et al. d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 57(6), 577-585 (2005). (Pubitemid 40409697)
-
(2005)
Biological Psychiatry
, vol.57
, Issue.6
, pp. 577-585
-
-
Heresco-Levy, U.1
Javitt, D.C.2
Ebstein, R.3
Vass, A.4
Lichtenberg, P.5
Bar, G.6
Catinari, S.7
Ermilov, M.8
-
167
-
-
27744529018
-
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study
-
DOI 10.1001/archpsyc.62.11.1196
-
Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 62(11), 1196-1204 (2005). (Pubitemid 41586919)
-
(2005)
Archives of General Psychiatry
, vol.62
, Issue.11
, pp. 1196-1204
-
-
Lane, H.-Y.1
Chang, Y.-C.2
Liu, Y.-C.3
Chiu, C.-C.4
Tsai, G.E.5
-
168
-
-
77953545879
-
Arandomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia
-
Lane HY, Lin CH, Huang YJ et al. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 13(4), 451-460 (2010).
-
(2010)
Int. J. Neuropsychopharmacol.
, vol.13
, Issue.4
, pp. 451-460
-
-
Lane, H.Y.1
Lin, C.H.2
Huang, Y.J.3
-
169
-
-
33748751382
-
Glycine transporter i inhibitor N-methylglycine (sarcosine) added to clozapine for the treatment of schizophrenia
-
Lane HY, Huang CL, Wu PL et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry 60(6), 645-649 (2006).
-
(2006)
Biol. Psychiatry
, vol.60
, Issue.6
, pp. 645-649
-
-
Lane, H.Y.1
Huang, C.L.2
Wu, P.L.3
-
170
-
-
0032974130
-
D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: A double-blind, parallel, placebo-controlled study
-
DOI 10.1016/S0893-133X(99)00014-7, PII S0893133X99000147
-
van Berckel BN, Evenblij CN, van Loon BJ et al. d-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21(2), 203-210 (1999). (Pubitemid 29304581)
-
(1999)
Neuropsychopharmacology
, vol.21
, Issue.2
, pp. 203-210
-
-
Van Berckel, B.N.M.1
Evenblij, C.N.2
Van Loon, B.J.A.M.3
Maas, M.F.4
Van Der Geld, M.A.M.5
Wynne, H.J.6
Van Ree, J.M.7
Kahn, R.S.8
-
171
-
-
0036184549
-
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia
-
DOI 10.1176/appi.ajp.159.3.480
-
Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am. J. Psychiatry 159(3), 480-482 (2002). (Pubitemid 34184748)
-
(2002)
American Journal of Psychiatry
, vol.159
, Issue.3
, pp. 480-482
-
-
Heresco-Levy, U.1
Ermilov, M.2
Shimoni, J.3
Shapira, B.4
Silipo, G.5
Javitt, D.C.6
-
172
-
-
20944441298
-
A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
-
DOI 10.1007/s00213-004-2032-2
-
Goff DC, Herz L, Posever T et al. A six-month, placebo-controlled trial of d-cycloserine coadministered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl.) 179(1), 144-150 (2005). (Pubitemid 40576701)
-
(2005)
Psychopharmacology
, vol.179
, Issue.1
, pp. 144-150
-
-
Goff, D.C.1
Herz, L.2
Posever, T.3
Shih, V.4
Tsai, G.5
Henderson, D.C.6
Freudenreich, O.7
Evins, A.E.8
Yovel, I.9
Zhang, H.10
Schoenfeld, D.11
-
173
-
-
56049099989
-
Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study
-
Goff DC, Cather C, Gottlieb JD et al. Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr. Res. 106(2-3), 320-327 (2008).
-
(2008)
Schizophr. Res.
, vol.106
, Issue.2-3
, pp. 320-327
-
-
Goff, D.C.1
Cather, C.2
Gottlieb, J.D.3
-
174
-
-
32144442536
-
D-alanine added to antipsychotics for the treatment of schizophrenia
-
DOI 10.1016/j.biopsych.2005.06.032, PII S0006322305008462
-
Tsai GE, Yang P, Chang YC, Chong MY. d-alanine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 59(3), 230-234 (2006). (Pubitemid 43208969)
-
(2006)
Biological Psychiatry
, vol.59
, Issue.3
, pp. 230-234
-
-
Tsai, G.E.1
Yang, P.2
Chang, Y.-C.3
Chong, M.-Y.4
-
175
-
-
0034796599
-
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia
-
DOI 10.1097/00004714-200110000-00005
-
Goff DC, Leahy L, Berman I et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J. Clin. Psychopharmacol. 21(5), 484-487 (2001). (Pubitemid 32937430)
-
(2001)
Journal of Clinical Psychopharmacology
, vol.21
, Issue.5
, pp. 484-487
-
-
Goff, D.C.1
Leahy, L.2
Berman, I.3
Posever, T.4
Herz, L.5
Leon, A.C.6
Johnson, S.A.7
Lynch, G.8
-
176
-
-
38149132338
-
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
-
Goff DC, Lamberti JS, Leon AC et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 33(3), 465-472 (2008).
-
(2008)
Neuropsychopharmacology
, vol.33
, Issue.3
, pp. 465-472
-
-
Goff, D.C.1
Lamberti, J.S.2
Leon, A.C.3
-
177
-
-
0035280803
-
Estrogen-a potential treatment for schizophrenia
-
Kulkarni J, Riedel A, de Castella AR et al. Estrogen-a potential treatment for schizophrenia. Schizophr. Res. 48(1), 137-144 (2001).
-
(2001)
Schizophr. Res.
, vol.48
, Issue.1
, pp. 137-144
-
-
Kulkarni, J.1
Riedel, A.2
De Castella, A.R.3
-
178
-
-
0141628394
-
Adjunctive estrogen treatment in women with chronic schizophrenia: A double-blind, randomized, and placebo-controlled trial
-
DOI 10.1016/S0278-5846(03)00161-1
-
Akhondzadeh S, Nejatisafa AA, Amini H et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(6), 1007-1012 (2003). (Pubitemid 37141389)
-
(2003)
Progress in Neuro-Psychopharmacology and Biological Psychiatry
, vol.27
, Issue.6
, pp. 1007-1012
-
-
Akhondzadeh, S.1
Nejatisafa, A.A.2
Amini, H.3
Mohammadi, M.R.4
Larijani, B.5
Kashani, L.6
Raisi, F.7
Kamalipour, A.8
-
179
-
-
0037312851
-
Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia
-
DOI 10.1001/archpsyc.60.2.133
-
Strous RD, Maayan R, Lapidus R et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch. Gen. Psychiatry 60(2), 133-141 (2003). (Pubitemid 36173119)
-
(2003)
Archives of General Psychiatry
, vol.60
, Issue.2
, pp. 133-141
-
-
Strous, R.D.1
Maayan, R.2
Lapidus, R.3
Stryjer, R.4
Lustig, M.5
Kotler, M.6
Weizman, A.7
-
180
-
-
33644874630
-
Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients
-
DOI 10.1097/01.wnf.0000188716.25211.58, PII 0000282620051100000003
-
Strous RD, Maayan R, Kotler M, Weizman A. Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients. Clin. Neuropharmacol. 28(6), 265-269 (2005). (Pubitemid 44378615)
-
(2005)
Clinical Neuropharmacology
, vol.28
, Issue.6
, pp. 265-269
-
-
Strous, R.D.1
Maayan, R.2
Kotler, M.3
Weizman, A.4
-
181
-
-
33748745743
-
Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: A randomized, double-blind, placebo-controlled, crossover trial
-
DOI 10.1097/01.jcp.0000237942.50270.35, PII 0000471420061000000010
-
Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J. Clin. Psychopharmacol. 26(5), 495-499 (2006). (Pubitemid 44401470)
-
(2006)
Journal of Clinical Psychopharmacology
, vol.26
, Issue.5
, pp. 495-499
-
-
Ritsner, M.S.1
Gibel, A.2
Ratner, Y.3
Tsinovoy, G.4
Strous, R.D.5
-
182
-
-
33847048555
-
Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: A randomized, double-blind placebo controlled trial
-
DOI 10.1016/j.psyneuen.2006.11.002, PII S030645300600196X
-
Strous RD, Stryjer R, Maayan R et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 32(2), 96-105 (2007). (Pubitemid 46274013)
-
(2007)
Psychoneuroendocrinology
, vol.32
, Issue.2
, pp. 96-105
-
-
Strous, R.D.1
Stryjer, R.2
Maayan, R.3
Gal, G.4
Viglin, D.5
Katz, E.6
Eisner, D.7
Weizman, A.8
-
183
-
-
54449085337
-
Short-term testosterone augmentation in male schizophrenics: A randomized, double-blind, placebo-controlled trial
-
Ko YH, Lew YM, Jung SW et al. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 28(4), 375-383 (2008).
-
(2008)
J. Clin. Psychopharmacol.
, vol.28
, Issue.4
, pp. 375-383
-
-
Ko, Y.H.1
Lew, Y.M.2
Jung, S.W.3
-
184
-
-
48949095082
-
Estrogen in severe mental illness: A potential new treatment approach
-
Kulkarni J, de Castella A, Fitzgerald PB et al. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 65(8), 955-960 (2008).
-
(2008)
Arch. Gen. Psychiatry
, vol.65
, Issue.8
, pp. 955-960
-
-
Kulkarni, J.1
De Castella, A.2
Fitzgerald, P.B.3
-
185
-
-
67449123074
-
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia
-
Marx CE, Keefe RS, Buchanan RW et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 34(8), 1885-1903 (2009).
-
(2009)
Neuropsychopharmacology
, vol.34
, Issue.8
, pp. 1885-1903
-
-
Marx, C.E.1
Keefe, R.S.2
Buchanan, R.W.3
-
186
-
-
77955575168
-
Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia
-
Kulkarni J, Gurvich C, Lee SJ et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35(8), 1142-1147 (2010).
-
(2010)
Psychoneuroendocrinology
, vol.35
, Issue.8
, pp. 1142-1147
-
-
Kulkarni, J.1
Gurvich, C.2
Lee, S.J.3
-
187
-
-
74549188501
-
Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: An 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial
-
Ritsner MS, Gibel A, Shleifer T et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J. Clin. Psychiatry 71(10), 1351-1362 (2010).
-
(2010)
J. Clin. Psychiatry
, vol.71
, Issue.10
, pp. 1351-1362
-
-
Ritsner, M.S.1
Gibel, A.2
Shleifer, T.3
-
188
-
-
0035190361
-
A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia
-
DOI 10.1176/appi.ajp.158.12.2071
-
Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 158(12), 2071-2074 (2001). (Pubitemid 33104119)
-
(2001)
American Journal of Psychiatry
, vol.158
, Issue.12
, pp. 2071-2074
-
-
Fenton, W.S.1
Dickerson, F.2
Boronow, J.3
Hibbeln, J.R.4
Knable, M.5
-
189
-
-
0036712807
-
Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia
-
DOI 10.1176/appi.ajp.159.9.1596
-
Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 159(9), 1596-1598 (2002). (Pubitemid 35006744)
-
(2002)
American Journal of Psychiatry
, vol.159
, Issue.9
, pp. 1596-1598
-
-
Emsley, R.1
Myburgh, C.2
Oosthuizen, P.3
Van Rensburg, S.J.4
-
190
-
-
0027200994
-
Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients
-
Rapaport MH, Wolkowitz O, Kelsoe JR, Pato C, Konicki PE, Pickar D. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients. Neuropsychopharmacology 9(2), 111-115 (1993). (Pubitemid 23275836)
-
(1993)
Neuropsychopharmacology
, vol.9
, Issue.2
, pp. 111-115
-
-
Rapaport, M.H.1
Wolkowitz, O.2
Kelsoe, J.R.3
Pato, C.4
Konicki, P.E.5
Pickar, D.6
-
191
-
-
0031860344
-
Naltrexone augmentation of neuroleptics in schizophrenia
-
DOI 10.1097/00004714-199806000-00011
-
Sernyak MJ, Glazer WM, Heninger GR et al. Naltrexone augmentation of neuroleptics in schizophrenia. J. Clin. Psychopharmacol. 18(3), 248-251 (1998). (Pubitemid 28266892)
-
(1998)
Journal of Clinical Psychopharmacology
, vol.18
, Issue.3
, pp. 248-251
-
-
Sernyak, M.J.1
Glazer, W.M.2
Heninger, G.R.3
Charney, D.S.4
Woods, S.W.5
Petrakis, I.L.6
Krystal, J.H.7
Price, L.H.8
-
192
-
-
12144290655
-
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia
-
Petrakis IL, O'Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl.) 172(3), 291-297 (2004). (Pubitemid 38392322)
-
(2004)
Psychopharmacology
, vol.172
, Issue.3
, pp. 291-297
-
-
Petrakis, I.L.1
O'Malley, S.2
Rounsaville, B.3
Poling, J.4
McHugh-Strong, C.5
Krystal, J.H.6
Congdon, D.7
Cooney, N.8
Gil, R.9
Keegan, K.10
Miles, D.11
Oville, A.12
Peluse, B.13
Trevisan, L.14
Gordon, L.15
Reino, J.16
Costello, W.17
Cryan, C.18
Desai, N.19
Losardo, M.20
Farrell, D.21
Rofman, B.E.22
Costello, W.23
more..
-
193
-
-
0346876282
-
Secretin for refractory schizophrenia
-
DOI 10.1016/S0920-9964(03)00068-9
-
Sheitman BB, Knable MB, Jarskog LF et al. Secretin for refractory schizophrenia. Schizophr. Res. 66(2-3), 177-181 (2004). (Pubitemid 38041117)
-
(2004)
Schizophrenia Research
, vol.66
, Issue.2-3
, pp. 177-181
-
-
Sheitman, B.B.1
Knable, M.B.2
Jarskog, L.F.3
Chakos, M.4
Boyce, L.H.5
Early, J.6
Lieberman, J.A.7
-
194
-
-
77956932186
-
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients
-
Feifel D, Macdonald K, Nguyen A et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 68(7), 678-680 (2010).
-
(2010)
Biol. Psychiatry
, vol.68
, Issue.7
, pp. 678-680
-
-
Feifel, D.1
MacDonald, K.2
Nguyen, A.3
-
195
-
-
0034069595
-
Dipyridamole in the treatment of schizophrenia: Adenosine-dopamine receptor interactions
-
DOI 10.1046/j.1365-2710.2000.00273.x
-
Akhondzadeh S, Shasavand E, Jamilian H, Shabestari O, Kamalipour A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J. Clin. Pharm. Ther. 25(2), 131-137 (2000). (Pubitemid 30326413)
-
(2000)
Journal of Clinical Pharmacy and Therapeutics
, vol.25
, Issue.2
, pp. 131-137
-
-
Akhondzadeh, S.1
Shasavand, E.2
Jamilian, H.-R.3
Shabestari, O.4
Kamalipour, A.5
-
196
-
-
13444259750
-
Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: A double blind, randomized and placebo controlled trial
-
DOI 10.1016/j.pnpbp.2004.11.008
-
Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(2), 253-259 (2005). (Pubitemid 40202911)
-
(2005)
Progress in Neuro-Psychopharmacology and Biological Psychiatry
, vol.29
, Issue.2
, pp. 253-259
-
-
Akhondzadeh, S.1
Safarcherati, A.2
Amini, H.3
-
197
-
-
14644406149
-
A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia
-
Brunstein MG, Ghisolfi ES, Ramos FL, Lara DR. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J. Clin. Psychiatry 66(2), 213-219 (2005). (Pubitemid 40314328)
-
(2005)
Journal of Clinical Psychiatry
, vol.66
, Issue.2
, pp. 213-219
-
-
Brunstein, M.G.1
Ghisolfi, E.S.2
Ramos, F.L.P.3
Lara, D.R.4
-
198
-
-
39749108012
-
A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia
-
DOI 10.1016/j.pnpbp.2007.11.021, PII S0278584607004113
-
Salimi S, Fotouhi A, Ghoreishi A et al. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(3), 726-732 (2008). (Pubitemid 351312372)
-
(2008)
Progress in Neuro-Psychopharmacology and Biological Psychiatry
, vol.32
, Issue.3
, pp. 726-732
-
-
Salimi, S.1
Fotouhi, A.2
Ghoreishi, A.3
Derakhshan, M.-K.4
Khodaie-Ardakani, M.-R.5
Mohammadi, M.-R.6
Noorbala, A.-A.7
Ahmadi-Abhari, S.-A.8
Hajiazim, M.9
Abbasi, S.-H.10
Akhondzadeh, S.11
-
199
-
-
62649140849
-
A double-blind trial of adjunctive allopurinol for schizophrenia
-
Dickerson FB, Stallings CR, Origoni AE et al. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophr. Res. 109(1-3), 66-69 (2009).
-
(2009)
Schizophr. Res.
, vol.109
, Issue.1-3
, pp. 66-69
-
-
Dickerson, F.B.1
Stallings, C.R.2
Origoni, A.E.3
-
200
-
-
0034810016
-
Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment
-
DOI 10.1176/appi.ajp.158.10.1722
-
Sumiyoshi T, Matsui M, Nohara S et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry 158(10), 1722-1725 (2001). (Pubitemid 32923670)
-
(2001)
American Journal of Psychiatry
, vol.158
, Issue.10
, pp. 1722-1725
-
-
Sumiyoshi, T.1
Matsui, M.2
Nohara, S.3
Yamashita, I.4
Kurachi, M.5
Sumiyoshi, C.6
Jayathilake, K.7
Meltzer, H.Y.8
-
201
-
-
34548189417
-
1A partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study
-
DOI 10.1016/j.schres.2007.06.008, PII S0920996407002630
-
Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 95(1-3), 158-168 (2007). (Pubitemid 47313647)
-
(2007)
Schizophrenia Research
, vol.95
, Issue.1-3
, pp. 158-168
-
-
Sumiyoshi, T.1
Park, S.2
Jayathilake, K.3
Roy, A.4
Ertugrul, A.5
Meltzer, H.Y.6
-
202
-
-
70349544018
-
Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist
-
Piskuli D, Olver JS, Maruff P, Norman TR. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist. Hum. Psychopharmacol. 24(6), 437-446 (2009).
-
(2009)
Hum. Psychopharmacol.
, vol.24
, Issue.6
, pp. 437-446
-
-
Piskuli, D.1
Olver, J.S.2
Maruff, P.3
Norman, T.R.4
-
203
-
-
78649371717
-
A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia
-
Ghaleiha A, Noorbala AA, Farnaghi F, Hajiazim M, Akhondzadeh S. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 30(6), 678-682 (2010).
-
(2010)
J. Clin. Psychopharmacol.
, vol.30
, Issue.6
, pp. 678-682
-
-
Ghaleiha, A.1
Noorbala, A.A.2
Farnaghi, F.3
Hajiazim, M.4
Akhondzadeh, S.5
-
204
-
-
33750609681
-
Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study
-
DOI 10.1016/j.schres.2006.07.010, PII S0920996406003173
-
Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr. Res. 88(1-3), 102-110 (2006). (Pubitemid 44693244)
-
(2006)
Schizophrenia Research
, vol.88
, Issue.1-3
, pp. 102-110
-
-
Zhang, Z.-J.1
Kang, W.-H.2
Li, Q.3
Wang, X.-Y.4
Yao, S.-M.5
Ma, A.-Q.6
-
205
-
-
58349098103
-
Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial
-
Akhondzadeh S, Mohammadi N, Noroozian M et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr. Res. 107(2-3), 206-212 (2009).
-
(2009)
Schizophr. Res.
, vol.107
, Issue.2-3
, pp. 206-212
-
-
Akhondzadeh, S.1
Mohammadi, N.2
Noroozian, M.3
-
206
-
-
22744432869
-
Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications
-
Sevy S, Rosenthal MH, Alvir J et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J. Clin. Psychiatry 66(7), 839-843 (2005). (Pubitemid 41032824)
-
(2005)
Journal of Clinical Psychiatry
, vol.66
, Issue.7
, pp. 839-843
-
-
Sevy, S.1
Rosenthal, M.H.2
Alvir, J.3
Meyer, S.4
Visweswaraiah, H.5
Gunduz-Bruce, H.6
Schooler, N.R.7
-
207
-
-
34249661792
-
A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia
-
Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J. Clin. Psychiatry 68(5), 705-710 (2007). (Pubitemid 46841853)
-
(2007)
Journal of Clinical Psychiatry
, vol.68
, Issue.5
, pp. 705-710
-
-
Pierre, J.M.1
Peloian, J.H.2
Wirshing, D.A.3
Wirshing, W.C.4
Marder, S.R.5
-
208
-
-
74549156560
-
Modafinil for clozapine-treated schizophrenia patients: A double-blind, placebo-controlled pilot trial
-
Freudenreich O, Henderson DC, Macklin EA et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J. Clin. Psychiatry 70(12), 1674-1680 (2009).
-
(2009)
J. Clin. Psychiatry
, vol.70
, Issue.12
, pp. 1674-1680
-
-
Freudenreich, O.1
Henderson, D.C.2
MacKlin, E.A.3
-
209
-
-
78649773228
-
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: A 4-week, double-blind, placebo-controlled study
-
Kane JM, D'Souza DC, Patkar AA et al. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J. Clin. Psychiatry 71(11), 1475-1481 (2010).
-
(2010)
J. Clin. Psychiatry
, vol.71
, Issue.11
, pp. 1475-1481
-
-
Kane, J.M.1
D'Souza, D.C.2
Patkar, A.A.3
-
210
-
-
26944441259
-
A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients
-
DOI 10.1097/00004850-200511000-00007
-
Silver H, Goodman C, Isakov V, Knoll G, Modai I. A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients. Int. Clin. Psychopharmacol. 20(6), 319-326 (2005). (Pubitemid 41475322)
-
(2005)
International Clinical Psychopharmacology
, vol.20
, Issue.6
, pp. 319-326
-
-
Silver, H.1
Goodman, C.2
Isakov, V.3
Knoll, G.4
Modai, I.5
-
211
-
-
34347351060
-
Lack of efficacy of 5 grams daily of creatine in schizophrenia: A randomized, double-blind, placebo-controlled trial
-
Kaptsan A, Odessky A, Osher Y, Levine J. Lack of efficacy of 5 grams daily of creatine in schizophrenia: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 68(6), 881-884 (2007). (Pubitemid 47015487)
-
(2007)
Journal of Clinical Psychiatry
, vol.68
, Issue.6
, pp. 881-884
-
-
Kaptsan, A.1
Odessky, A.2
Osher, Y.3
Levine, J.4
-
212
-
-
0032907201
-
Cyproheptadine in treatment of chronic schizophrenia: A double-blind, placebo-controlled study
-
DOI 10.1046/j.1365-2710.1999.00197.x
-
Akhondzadeh S, Mohammadi MR, Amini-Nooshabadi H, Davari-Ashtiani R. Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. J. Clin. Pharm. Ther. 24(1), 49-52 (1999). (Pubitemid 29171679)
-
(1999)
Journal of Clinical Pharmacy and Therapeutics
, vol.24
, Issue.1
, pp. 49-52
-
-
Akhondzadeh, S.1
Mohammadi, M.R.2
Amini-Nooshabadi, H.3
Davari-Ashtiani, R.4
-
213
-
-
0029317806
-
Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: A double-blind placebo-controlled study
-
Lee HS, Song DH, Kim JH, Lee YM, Han ES, Yoo KJ. Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol. 10(2), 67-72 (1995).
-
(1995)
Int. Clin. Psychopharmacol.
, vol.10
, Issue.2
, pp. 67-72
-
-
Lee, H.S.1
Song, D.H.2
Kim, J.H.3
Lee, Y.M.4
Han, E.S.5
Yoo, K.J.6
-
214
-
-
0036458709
-
Diazoxide in the treatment of schizophrenia: Novel application of potassium channel openers in the treatment of schizophrenia
-
DOI 10.1046/j.1365-2710.2002.00445.x
-
Akhondzadeh S, Mojtahedzadeh V, Mirsepassi GR, Moin M, Amini-Nooshabadi H, Kamalipour A. Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. J. Clin. Pharm. Ther. 27(6), 453-459 (2002). (Pubitemid 35463898)
-
(2002)
Journal of Clinical Pharmacy and Therapeutics
, vol.27
, Issue.6
, pp. 453-459
-
-
Akhondzadeh, S.1
Mojtahedzadeh, V.2
Mirsepassi, G.-R.3
Moin, M.4
Amini-Nooshabadi, H.5
Kamalipour, A.6
-
215
-
-
77649112679
-
A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia
-
Levkovitz Y, Mendlovich S, Riwkes S et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J. Clin. Psychiatry 71(2), 138-149 (2010).
-
(2010)
J. Clin. Psychiatry
, vol.71
, Issue.2
, pp. 138-149
-
-
Levkovitz, Y.1
Mendlovich, S.2
Riwkes, S.3
-
216
-
-
79551525420
-
L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: An 8-week, randomized, double-blind, placebo-controlled, 2-center study
-
Ritsner MS, Miodownik C, Ratner Y et al. l-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J. Clin. Psychiatry 72(1), 34-42 (2011).
-
(2011)
J. Clin. Psychiatry
, vol.72
, Issue.1
, pp. 34-42
-
-
Ritsner, M.S.1
Miodownik, C.2
Ratner, Y.3
-
217
-
-
48749112603
-
N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
-
Berk M, Copolov D, Dean O et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 64(5), 361-368 (2008).
-
(2008)
Biol. Psychiatry
, vol.64
, Issue.5
, pp. 361-368
-
-
Berk, M.1
Copolov, D.2
Dean, O.3
-
218
-
-
0032708893
-
Piracetam in the treatment of schizophrenia: Implications for the glutamate hypothesis of schizophrenia
-
DOI 10.1046/j.1365-2710.1999.00238.x
-
Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, Amini-Nooshabadi H. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J. Clin. Pharm. Ther. 24(5), 369-374 (1999). (Pubitemid 29520787)
-
(1999)
Journal of Clinical Pharmacy and Therapeutics
, vol.24
, Issue.5
, pp. 369-374
-
-
Noorbala, A.A.1
Akhondzadeh, S.2
Davari-Ashtiani, R.3
Amini-Nooshabadi, H.4
-
219
-
-
33846550774
-
Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin
-
DOI 10.1038/sj.mp.4001907, PII 4001907
-
Ehrenreich H, Hinze-Selch D, Stawicki S et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol. Psychiatry 12(2), 206-220 (2007). (Pubitemid 46160985)
-
(2007)
Molecular Psychiatry
, vol.12
, Issue.2
, pp. 206-220
-
-
Ehrenreich, H.1
Hinze-Selch, D.2
Stawicki, S.3
Aust, C.4
Knolle-Veentjer, S.5
Wilms, S.6
Heinz, G.7
Erdag, S.8
Jahn, H.9
Degner, D.10
Ritzen, M.11
Mohr, A.12
Wagner, M.13
Schneider, U.14
Bohn, M.15
Huber, M.16
Czernik, A.17
Pollmacher, T.18
Maier, W.19
Siren, A.-L.20
Klosterkotter, J.21
Falkai, P.22
Ruther, E.23
Aldenhoff, J.B.24
Krampe, H.25
more..
-
220
-
-
57049171917
-
Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia
-
Strous RD, Ritsner MS, Adler S et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur. Neuropsychopharmacol. 19(1), 14-22 (2009).
-
(2009)
Eur. Neuropsychopharmacol.
, vol.19
, Issue.1
, pp. 14-22
-
-
Strous, R.D.1
Ritsner, M.S.2
Adler, S.3
-
221
-
-
79952487439
-
Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled trial
-
Akhondzadeh S, Ghayyoumi R, Rezaei F et al. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology (Berl.) 213(4), 809-815 (2011).
-
(2011)
Psychopharmacology (Berl.)
, vol.213
, Issue.4
, pp. 809-815
-
-
Akhondzadeh, S.1
Ghayyoumi, R.2
Rezaei, F.3
-
222
-
-
77956864079
-
Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis
-
Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry 197(3), 174-179 (2010).
-
(2010)
Br. J. Psychiatry
, vol.197
, Issue.3
, pp. 174-179
-
-
Singh, S.P.1
Singh, V.2
Kar, N.3
Chan, K.4
-
223
-
-
80755140872
-
Chapter 15: Psychopharmacology and electroconvulsive therapy
-
Simon RI, Tardiff K (Eds), American Psychiatric Publishing, Inc., Arlington, VA, USA
-
Citrome L. Chapter 15: psychopharmacology and electroconvulsive therapy. In: Textbook of Violence Assessmentand Management. Simon RI, Tardiff K (Eds). American Psychiatric Publishing, Inc., Arlington, VA, USA, 301-323 (2008).
-
(2008)
Textbook of Violence Assessmentand Management
, pp. 301-323
-
-
Citrome, L.1
-
224
-
-
0033060951
-
Cognitive-behavioral therapy and clozapine for clients with treatment- refractory schizophrenia
-
Pinto A, La Pia S, Mennella R, Giorgio D, DeSimone L. Cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. Psychiatr. Serv. 50(7), 901-904 (1999). (Pubitemid 29309860)
-
(1999)
Psychiatric Services
, vol.50
, Issue.7
, pp. 901-904
-
-
Pinto, A.1
La Pia, S.2
Mennella, R.3
Giorgio, D.4
DeSimone, L.5
-
225
-
-
17144382810
-
Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication: Randomised controlled trial
-
DOI 10.1192/bjp.186.4.324
-
Valmaggia LR, van der Gaag M, Tarrier N, Pijnenborg M, Slooff CJ. Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. Br. J. Psychiatry 186, 324-330 (2005). (Pubitemid 40524012)
-
(2005)
British Journal of Psychiatry
, vol.186
, Issue.APR.
, pp. 324-330
-
-
Valmaggia, L.R.1
Van Der Gaag, M.2
Tarrier, N.3
Pijnenborg, M.4
Slooff, C.J.5
-
226
-
-
73449143556
-
A preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophrenia
-
Barretto EM, Kayo M, Avrichir BS et al. A preliminary controlled trial of cognitive behavioral therapy in clozapine-resistant schizophrenia. J. Nerv. Ment. Dis. 197(11), 865-868 (2009).
-
(2009)
J. Nerv. Ment. Dis.
, vol.197
, Issue.11
, pp. 865-868
-
-
Barretto, E.M.1
Kayo, M.2
Avrichir, B.S.3
-
227
-
-
0042203177
-
Continuation ECT in treatment-resistant schizophrenia: A controlled study
-
Chanpattana W, Chakrabhand ML, Sackeim HA et al. Continuation ECT in treatment-resistant schizophrenia: a controlled study. J. ECT 15(3), 178-192 (1999).
-
(1999)
J. ECT
, vol.15
, Issue.3
, pp. 178-192
-
-
Chanpattana, W.1
Chakrabhand, M.L.2
Sackeim, H.A.3
-
228
-
-
33749334000
-
Efficacy of Electroconvulsive Therapy in Treatment Resistant Schizophrenia: A double-blind study
-
Goswami U, Kumar U, Singh B. Efficacy of electroconvulsive therapy in treatment resistant schizophrenia: a double blind study. Indian J. Psychiatry 45(1), 26-29 (2003). (Pubitemid 36657671)
-
(2003)
Indian Journal of Psychiatry
, vol.45
, Issue.1
, pp. 26-29
-
-
Goswami, U.1
Kumar, U.2
Singh, B.3
-
229
-
-
3142758581
-
Transcranial magnetic stimulation for auditory hallucinations in schizophrenia
-
DOI 10.1016/j.psychres.2004.03.005, PII S0165178104000770
-
McIntosh AM, Semple D, Tasker K et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Res. 127(1-2), 9-17 (2004). (Pubitemid 38916862)
-
(2004)
Psychiatry Research
, vol.127
, Issue.1-2
, pp. 9-17
-
-
McIntosh, A.M.1
Semple, D.2
Tasker, K.3
Harrison, L.K.4
Owens, D.G.C.5
Johnstone, E.C.6
Ebmeier, K.P.7
-
230
-
-
23044439239
-
A double-blind sham-controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations
-
DOI 10.1097/01.jcp.0000168487.22140.7f
-
Fitzgerald PB, Benitez J, Daskalakis JZ et al. A double-blind sham-controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. J. Clin. Psychopharmacol. 25(4), 358-362 (2005). (Pubitemid 41060256)
-
(2005)
Journal of Clinical Psychopharmacology
, vol.25
, Issue.4
, pp. 358-362
-
-
Fitzgerald, P.B.1
Benitez, J.2
Daskalakis, J.Z.3
Brown, T.L.4
Marston, N.A.U.5
De Castella, A.6
Kulkarni, J.7
-
231
-
-
13844266333
-
A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment-refractory auditory hallucinations
-
DOI 10.1016/j.neulet.2004.11.048
-
Lee SH, Kim W, Chung YC et al. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment-refractory auditory hallucinations. Neurosci. Lett. 376(3), 177-181 (2005). (Pubitemid 40255305)
-
(2005)
Neuroscience Letters
, vol.376
, Issue.3
, pp. 177-181
-
-
Lee, S.-H.1
Kim, W.2
Chung, Y.-C.3
Jung, K.-H.4
Bahk, W.-M.5
Jun, T.-Y.6
Kim, K.-S.7
George, M.S.8
Chae, J.-H.9
-
232
-
-
31644435639
-
Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: A double blind sham controlled study
-
DOI 10.1016/j.jpsychires.2005.02.008, PII S0022395605000427
-
Saba G, Verdon CM, Kalalou K et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. J. Psychiatr. Res. 40(2), 147-152 (2006). (Pubitemid 43172876)
-
(2006)
Journal of Psychiatric Research
, vol.40
, Issue.2
, pp. 147-152
-
-
Saba, G.1
Verdon, C.M.2
Kalalou, K.3
Rocamora, J.F.4
Dumortier, G.5
Benadhira, R.6
Stamatiadis, L.7
Vicaut, E.8
Lipski, H.9
Januel, D.10
-
233
-
-
34249340096
-
Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study
-
DOI 10.1016/j.schres.2007.03.016, PII S0920996407001478
-
Mogg A, Purvis R, Eranti S et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. Schizophr. Res. 93(1-3), 221-228 (2007). (Pubitemid 46817960)
-
(2007)
Schizophrenia Research
, vol.93
, Issue.1-3
, pp. 221-228
-
-
Mogg, A.1
Purvis, R.2
Eranti, S.3
Contell, F.4
Taylor, J.P.5
Nicholson, T.6
Brown, R.G.7
McLoughlin, D.M.8
-
234
-
-
34548178664
-
Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study
-
DOI 10.1016/j.schres.2007.06.019, PII S0920996407002733
-
Prikryl R, Kasparek T, Sketakova S et al. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study. Schizophr. Res. 95(1-3), 151-157 (2007). (Pubitemid 47313654)
-
(2007)
Schizophrenia Research
, vol.95
, Issue.1-3
, pp. 151-157
-
-
Prikryl, R.1
Kasparek, T.2
Skotakova, S.3
Ustohal, L.4
Kucerova, H.5
Ceskova, E.6
-
235
-
-
35948993005
-
Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine
-
Rosa MO, Gattaz WF, Rosa MA et al. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. J. Clin. Psychiatry 68(10), 1528-1532 (2007). (Pubitemid 350073400)
-
(2007)
Journal of Clinical Psychiatry
, vol.68
, Issue.10
, pp. 1528-1532
-
-
Rosa, M.O.1
Gattaz, W.F.2
Rosa, M.A.3
Rumi, D.O.4
Tavares, H.5
Myczkowski, M.6
Sartorelli, M.C.7
Rigonatti, S.P.8
Elkis, H.9
Cabral, S.B.10
Teixeira, M.J.11
Marcolin, M.A.12
-
236
-
-
45949097437
-
A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia
-
DOI 10.1016/j.brs.2007.08.001, PII S1935861X07000022
-
Fitzgerald PB, Herring S, Hoy K et al. A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimul. 1(1), 27-32 (2008). (Pubitemid 351966358)
-
(2008)
Brain Stimulation
, vol.1
, Issue.1
, pp. 27-32
-
-
Fitzgerald, P.B.1
Herring, S.2
Hoy, K.3
McQueen, S.4
Segrave, R.5
Kulkarni, J.6
Daskalakis, Z.J.7
-
237
-
-
43749112352
-
Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4-week randomized placebo controlled study
-
DOI 10.1016/j.brs.2008.01.001, PII S1935861X08000028
-
Schneider AL, Schneider TL, Stark H. Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: a 4-week randomized placebo controlled study. Brain Stimul. 1(2), 106-111 (2008). (Pubitemid 351689965)
-
(2008)
Brain Stimulation
, vol.1
, Issue.2
, pp. 106-111
-
-
Schneider, A.L.1
Schneider, T.L.2
Stark, H.3
-
238
-
-
69849086472
-
Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory-verbal hallucinations in schizophrenia: A randomized controlled trial
-
Vercammen A, Knegtering H, Bruggeman R et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory-verbal hallucinations in schizophrenia: a randomized controlled trial. Schizophr. Res. 114(1-3), 172-179 (2009).
-
(2009)
Schizophr. Res.
, vol.114
, Issue.1-3
, pp. 172-179
-
-
Vercammen, A.1
Knegtering, H.2
Bruggeman, R.3
-
239
-
-
79958249150
-
A pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine
-
DOI: 10.1016/j.psychres.2010.11.022 Epub ahead of print
-
De Jesus DR, Gil A, Barbosa L et al. A pilot double-blind sham-controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Res. DOI: 10.1016/j.psychres.2010.11.022 (2010) (Epub ahead of print).
-
(2010)
Psychiatry Res.
-
-
De Jesus, D.R.1
Gil, A.2
Barbosa, L.3
-
240
-
-
33645542970
-
"Hitting" voices of schizophrenia patients may lastingly reduce persistent auditory hallucinations and their burden: 18-Month outcome of a randomized controlled trial
-
Jenner JA, Nienhuis FJ, van de Willige G, Wiersma D. "Hitting" voices of schizophrenia patients may lastingly reduce persistent auditory hallucinations and their burden: 18-month outcome of a randomized controlled trial. Can. J. Psychiatry 51(3), 169-177 (2006).
-
(2006)
Can. J. Psychiatry
, vol.51
, Issue.3
, pp. 169-177
-
-
Jenner, J.A.1
Nienhuis, F.J.2
Van De Willige, G.3
Wiersma, D.4
-
241
-
-
77958187804
-
Neuroplasticity-based cognitive training in schizophrenia: An interim report on the effects 6 months later
-
Fisher M, Holland C, Subramaniam K, Vinogradov S. Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. Schizophr. Bull. 36(4), 869-879 (2010).
-
(2010)
Schizophr. Bull.
, vol.36
, Issue.4
, pp. 869-879
-
-
Fisher, M.1
Holland, C.2
Subramaniam, K.3
Vinogradov, S.4
-
242
-
-
0037350926
-
Randomized controlled trial of occupational therapy in patients with treatment-resistant schizophrenia
-
Buchain PC, Vizzotto AD, Henna Neto J, Elkis H. Randomized controlled trial of occupational therapy in patients with treatment-resistant schizophrenia. Rev. Bras. Psiquiatr. 25(1), 26-30 (2003). (Pubitemid 36396144)
-
(2003)
Revista Brasileira de Psiquiatria
, vol.25
, Issue.1
, pp. 26-30
-
-
Buchain, P.C.1
Vizzotto, A.D.B.2
Neto, J.H.3
Elkis, H.4
-
243
-
-
20444382433
-
The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia
-
DOI 10.1097/01.yct.0000165500.60784.05
-
Braga RJ, Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J. ECT 21(2), 75-83 (2005). (Pubitemid 40800031)
-
(2005)
Journal of ECT
, vol.21
, Issue.2
, pp. 75-83
-
-
Braga, R.J.1
Petrides, G.2
-
244
-
-
77951029973
-
Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: Review and meta-analysis
-
Dlabac-de Lange JJ, Knegtering R, Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J. Clin. Psychiatry 71(4), 411-418 (2010).
-
(2010)
J. Clin. Psychiatry
, vol.71
, Issue.4
, pp. 411-418
-
-
Dlabac-De Lange, J.J.1
Knegtering, R.2
Aleman, A.3
-
245
-
-
60249097465
-
Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia
-
Freitas C, Fregni F, Pascual-Leone A. Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr. Res. 108(1-3), 11-24 (2009).
-
(2009)
Schizophr. Res.
, vol.108
, Issue.1-3
, pp. 11-24
-
-
Freitas, C.1
Fregni, F.2
Pascual-Leone, A.3
-
246
-
-
37849188208
-
Treatment resistance in schizophrenia: The role of alternative therapies
-
37
-
Greenberg WM. Treatment resistance in schizophrenia: the role of alternative therapies. Psychiatric Times 23(11), 37, 40-42 (2006).
-
(2006)
Psychiatric Times
, vol.23
, Issue.11
, pp. 40-42
-
-
Greenberg, W.M.1
-
247
-
-
77949659512
-
Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia
-
Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int. J. Neuropsychopharmacol. 13(2), 257-271 (2010).
-
(2010)
Int. J. Neuropsychopharmacol.
, vol.13
, Issue.2
, pp. 257-271
-
-
Singh, V.1
Singh, S.P.2
Chan, K.3
-
248
-
-
67749114569
-
Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: An open-label study
-
Miyaoka T, Furuya M, Yasuda H et al. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study. Clin. Neuropharmacol. 32(1), 6-9 (2009).
-
(2009)
Clin. Neuropharmacol.
, vol.32
, Issue.1
, pp. 6-9
-
-
Miyaoka, T.1
Furuya, M.2
Yasuda, H.3
-
249
-
-
0033062010
-
Megavitamin and dietary treatment in schizophrenia: A randomised, controlled trial
-
DOI 10.1046/j.1440-1614.1999.00527.x
-
Vaughan K, McConaghy N. Megavitamin and dietary treatment in schizophrenia: a randomised, controlled trial. Aust. NZ J. Psychiatry 33(1), 84-88 (1999). (Pubitemid 29121904)
-
(1999)
Australian and New Zealand Journal of Psychiatry
, vol.33
, Issue.1
, pp. 84-88
-
-
Vaughan, K.1
McConaghy, N.2
-
250
-
-
70349958161
-
Acupuncture for schizophrenia: A systematic review and meta-analysis
-
Lee MS, Shin BC, Ronan P, Ernst E. Acupuncture for schizophrenia: a systematic review and meta-analysis. Int. J. Clin. Pract. 63(11), 1622-1633 (2009).
-
(2009)
Int. J. Clin. Pract.
, vol.63
, Issue.11
, pp. 1622-1633
-
-
Lee, M.S.1
Shin, B.C.2
Ronan, P.3
Ernst, E.4
-
251
-
-
34547114455
-
Yoga therapy as an add-on treatment in the management of patients with schizophrenia - A randomized controlled trial
-
DOI 10.1111/j.1600-0447.2007.01032.x
-
Duraiswamy G, Thirthalli J, Nagendra HR, Gangadhar BN. Yoga therapy as an add-on treatment in the management of patients with schizophrenia-a randomized controlled trial. Acta Psychiatr. Scand. 116(3), 226-232 (2007). (Pubitemid 47106661)
-
(2007)
Acta Psychiatrica Scandinavica
, vol.116
, Issue.3
, pp. 226-232
-
-
Duraiswamy, G.1
Thirthalli, J.2
Nagendra, H.R.3
Gangadhar, B.N.4
-
252
-
-
79955116386
-
Iloperidone, asenapine and lurasidone. A brief overview of three new second-generation antipsychotics
-
Citrome L. Iloperidone, asenapine and lurasidone. A brief overview of three new second-generation antipsychotics. Postgrad. Med. 123(2), 153-162 (2011).
-
(2011)
Postgrad. Med.
, vol.123
, Issue.2
, pp. 153-162
-
-
Citrome, L.1
-
253
-
-
77954105828
-
Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression
-
Gründer G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr. Opin. Investig. Drugs. 11(7), 823-832 (2010).
-
(2010)
Curr. Opin. Investig. Drugs.
, vol.11
, Issue.7
, pp. 823-832
-
-
Gründer, G.1
-
254
-
-
34948858402
-
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial
-
DOI 10.1038/nm1632, PII NM1632
-
Patil ST, Zhang L, Martenyi F et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13(9), 1102-1107 (2007). (Pubitemid 47517511)
-
(2007)
Nature Medicine
, vol.13
, Issue.9
, pp. 1102-1107
-
-
Patil, S.T.1
Zhang, L.2
Martenyi, F.3
Lowe, S.L.4
Jackson, K.A.5
Andreev, B.V.6
Avedisova, A.S.7
Bardenstein, L.M.8
Gurovich, I.Y.9
Morozova, M.A.10
Mosolov, S.N.11
Neznanov, N.G.12
Reznik, A.M.13
Smulevich, A.B.14
Tochilov, V.A.15
Johnson, B.G.16
Monn, J.A.17
Schoepp, D.D.18
-
255
-
-
77957674463
-
Thinking glutamatergically: Changing concepts of schizophrenia based upon changing neurochemical models
-
Kantrowitz JT, Javitt DC. Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. Clin. Schizophr. Relat. Psychoses 4(3), 189-200 (2010).
-
(2010)
Clin. Schizophr. Relat. Psychoses
, vol.4
, Issue.3
, pp. 189-200
-
-
Kantrowitz, J.T.1
Javitt, D.C.2
-
256
-
-
34447134211
-
Novel therapeutics for schizophrenia: Targeting glycine modulation of NMDA glutamate receptors
-
Stahl SM. Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. CNS Spectr. 12(6), 423-427 (2007). (Pubitemid 47035288)
-
(2007)
CNS Spectrums
, vol.12
, Issue.6
, pp. 423-427
-
-
Stahl, S.M.1
-
257
-
-
15944428993
-
Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action
-
Javitt DC, Duncan L, Balla A, Sershen H. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol. Psychiatry 10(3), 275-287 (2005).
-
(2005)
Mol. Psychiatry
, vol.10
, Issue.3
, pp. 275-287
-
-
Javitt, D.C.1
Duncan, L.2
Balla, A.3
Sershen, H.4
-
258
-
-
73449097085
-
Using oral ziprasidone effectively: The food effect and dose-response
-
Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv. Ther. 26(8), 739-748 (2009).
-
(2009)
Adv. Ther.
, vol.26
, Issue.8
, pp. 739-748
-
-
Citrome, L.1
|